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The Monte Carlo MC method has been shown through many research studies to calculate accurate
dose distributions for clinical radiotherapy, particularly in heterogeneous patient tissues where the
effects of electron transport cannot be accurately handled with conventional, deterministic dose
algorithms. Despite its proven accuracy and the potential for improved dose distributions to influ-
ence treatment outcomes, the long calculation times previously associated with MC simulation
rendered this method impractical for routine clinical treatment planning. However, the development
of faster codes optimized for radiotherapy calculations and improvements in computer processor
technology have substantially reduced calculation times to, in some instances, within minutes on a
single processor. These advances have motivated several major treatment planning system vendors
to embark upon the path of MC techniques. Several commercial vendors have already released or
are currently in the process of releasing MC algorithms for photon and/or electron beam treatment
planning. Consequently, the accessibility and use of MC treatment planning algorithms may well
become widespread in the radiotherapy community. With MC simulation, dose is computed sto-
chastically using first principles; this method is therefore quite different from conventional dose
algorithms. Issues such as statistical uncertainties, the use of variance reduction techniques, the
4818 4818Med. Phys. 34 „12…, December 2007 0094-2405/2007/34„12…/4818/36/$23.00 © 2007 Am. Assoc. Phys. Med.
4819 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4819ability to account for geometric details in the accelerator treatment head simulation, and other
features, are all unique components of a MC treatment planning algorithm. Successful implemen-
tation by the clinical physicist of such a system will require an understanding of the basic principles
of MC techniques. The purpose of this report, while providing education and review on the use of
MC simulation in radiotherapy planning, is to set out, for both users and developers, the salient
issues associated with clinical implementation and experimental verification of MC dose algo-
rithms. As the MC method is an emerging technology, this report is not meant to be prescriptive.
Rather, it is intended as a preliminary report to review the tenets of the MC method and to provide
the framework upon which to build a comprehensive program for commissioning and routine
quality assurance of MC-based treatment planning systems. © 2007 American Association of
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I. INTRODUCTION
I.A. Motivation
The accuracy of dose calculations is crucial to the quality of
treatment planning and consequently to the doses delivered
1to patients undergoing radiation therapy. Among other fac-
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mizing the therapeutic gain, i.e., maximizing the dose to the
tumor for a given normal-tissue dose, for patients treated
with radiation. Although the clinical benefit of more accurate
dose distributions i.e., how the improved dose distributions
will affect tumor recurrence, i.e., local control, and normal
tissue complications has not been adequately quantified and
requires further investigation, evidence exists that dose dif-
ferences on the order of 7% are clinically detectable.2 More-
over, several studies have shown that 5% changes in dose
can result in 10%−20% changes in tumor control probability
TCP or up to 20–30% changes in normal tissue complica-
tion probabilities NCTP if the prescribed dose falls along
the steepest region of the dose-effect curves.3–5 Readers in-
terested in further understanding the need for heterogeneity
corrections, among other topics related to dose calculations,
are encouraged to read the AAPM Report No. 85,1 where a
comprehensive review of tissue heterogeneity corrections for
megavoltage photon beams is provided.
In this report we focus our attention on the Monte Carlo
MC method, a dose calculation algorithm known to be very
accurate when used properly for treatment planning in het-
erogeneous patient tissues. The issue of lengthy calculation
times has traditionally led to the MC method being viewed in
the medical physics community as a clinically unfeasible ap-
proach. However, the development of MC codes optimized
for radiotherapy calculations as well as the availability of
much faster and affordable computers, have substantially re-
duced processing times. These significant advances have led
to the clinical use of MC algorithms at some treatment cen-
ters and the promised availability of MC photon/electron
planning modules among several commercial treatment plan-
ning vendors.
In light of the above considerations, MC treatment plan-
ning is quickly becoming a reality. An introductory report for
the medical physics community on the understanding, imple-
mentation, testing, and use of MC algorithms is therefore
warranted.
I.B. Objectives for the report
We intend this document to be a preliminary report with
the following objectives: a to provide an educational re-
view of the physics of the MC method and how it is applied
in external beam radiotherapy dose calculations, b to de-
scribe the role of the MC method in external beam radio-
therapy treatment planning process: from the interaction of
electrons in the target of the linear accelerator to the deposi-
tion of dose in the patient tissues, c to describe the issues
associated with MC dose calculation within the patient-
specific geometry, d to discuss the issues associated with
experimental verification of MC algorithms, and e to dis-
cuss the clinical implications of MC calculated dose distri-
butions.
We expect that areas of concern outlined in this report
will be further investigated and that more detailed reports
providing recommendations on the major issues will be
forthcoming.
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Following the introductory section Sec. I we begin in
Sec. II with a review of the MC method as it applies to
photon and electron transport. We include in this section an
overview of MC simulation from the accelerator treatment
head to the patient as well as a discussion of variance reduc-
tion techniques and efficiency-enhancing methods integral to
MC calculations in radiotherapy. Section III begins with a
review of the major MC codes being used in clinical appli-
cation and is followed by detailed discussions on accelerator
treatment head modeling and patient-specific treatment plan-
ning. This section concludes with the topic of experimental
verification, in which guidance is provided on the types of
tests needed to verify the accuracy of MC dose calculation
algorithms. In Sec. IV we provide a review of recent studies
demonstrating the potential clinical impact of MC dose cal-
culations in comparison with conventional algorithms. Fi-
nally, we conclude in Sec. V with a summary of the recom-
mendations from this task group report.
II. THE MONTE CARLO METHOD IN
RADIOTHERAPY DOSE CALCULATIONS
II.A. Definition of the MC method and historical
background
Most generally, the MC technique is a statistical method
for performing numerical integrations. MC simulations are
employed in many areas of science and technology. Although
a method based on random sampling was discussed as early
as 1777 by Buffon,6 the MC technique as we know it today
was first developed and named at the end of the second
world war. The motivation was to apply MC techniques to
radiation transport, specifically for nuclear weapons.7 The
driving forces for the initial idea appear to have been Stanis-
law Ulam and John von Neumann who saw the development
of ENIAC, the first electronic computer, as an ideal oppor-
tunity to develop new applications of statistical sampling.
The developments of MC techniques and computers have
been closely intertwined ever since, with an exponential in-
crease of the application of MC simulations since digital
computers became widely available in the 1950s and 1960s.
Modeling of particle transport problems is ideally suited
for the use of MC methods and has been described by Rogers
and Bielajew as follows: “The Monte Carlo technique for the
simulation of the transport of electrons and photons though
bulk media consists of using knowledge of the probability
distributions governing the individual interactions of elec-
trons and photons in materials to simulate the random trajec-
tories of individual particles. One keeps track of physical
quantities of interest for a large number of histories to pro-
vide the required information about the average quantities.”8
As a technique for calculating dose in a patient the underly-
ing physical basis is much simpler in concept than analytic
algorithms because the MC method consists of a straightfor-
ward simulation of reality and does not involve complex
approximations nor models of dose deposition, but only a
knowledge of the physics of the various interactions which
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While some of these interactions may be complex to simu-
late in detail, the basic ideas of each interaction, e.g., an
electron giving off a bremsstrahlung photon, are well under-
stood by medical physicists and, hence, the overall process is
easy to comprehend.
Although MC was used in several particle physics appli-
cations to simulate electron-photon showers in the 1950s, the
seminal paper in the field was that of Berger in 1963,9 in
which he described the condensed history technique for elec-
tron transport. This technique is the basis of all modern
electron-photon transport MC codes relevant to medical
physics. The ETRAN code, based on these ideas10 was devel-
oped by Berger and Seltzer and now forms the basis of elec-
tron transport in the MCNP code.11 The release of the EGS4
MC code system in 198512 served as a catalyst for the appli-
cation of the MC method in radiotherapy calculations of dose
and dosimeter response. The work of Petti et al.,13 Mohan et
al.,14 and Udale15 being early examples of the use of the EGS
MC code system12,16,17 to simulate medical linear accelera-
tors. Even without the direct use of MC simulations, the MC
method already plays a significant role in radiotherapy treat-
ment planning since the energy deposition kernels used in
convolution/superposition algorithms have been calculated
using MC techniques. Linear accelerator calibration proto-
cols e.g., AAPM’s TG-5118 use factors derived from MC
simulations. MC-based calculations are also used in the de-
sign of treatment head components.19,20
Although it has only recently become practical, for over
two decades the application of MC techniques to radiation
treatment planning has been quite clear.21,22 The widely used
BEAM code system23 is a pair of EGS4 now EGSnrc17 user
codes for simulating radiation transport in accelerators and in
patients represented by CT data sets. These relatively easy to
use tools have sparked intense research in MC-based radio-
therapy treatment planning and have lead to two comprehen-
sive reviews of accelerator simulations by Ma and Jiang24
and Verhaegen and Seuntjens.25 Kawrakow and Fippel,
among others, have provided the breakthroughs which have
made clinical treatment planning feasible, as discussed in
Sec. III A. The fast MC codes being developed commercially
are almost all based on the results of this collaboration. As
this report is being written, the first commercial MC systems
have already been introduced into routine clinical treatment
planning for electrons26 and photons.27
II.B. Monte Carlo simulation of electron and photon
transport
The following material represents a very brief introduc-
tion into the MC simulation of electron and photon transport.
For more details the reader is referred to the reviews avail-
able in the literature.8,28–31 Another source for detailed infor-
mation is the documentation accompanying some of the gen-
eral purpose codes, for instance, the EGSnrc,17 MCNP,32 and
GEANT4 Ref. 33 manuals, and the PENELOPE paper.34
In the energy range of interest for external beam radio-
therapy megavoltage range, photons interact with surround-
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scattering with atomic electrons, pair production in the
nuclear or electron electromagnetic field, photoelectric ab-
sorption, and coherent Rayleigh scattering. The first three
collision types transfer energy from the photon radiation field
to electrons or positrons. In most cases Compton scattering is
the dominant interaction, although pair production becomes
increasingly important with increasing energy, and may even
dominate at higher energies in high-Z components of the
treatment head of medical linear accelerators.
When electrons traverse matter, they undergo a large
number of elastic interactions and lose energy by two main
processes: inelastic collisions with atoms and molecules and
radiative interactions. Inelastic collisions result in excitations
and ionizations. Ionizations lead to secondary electrons,
sometimes referred to as “ particles”. Radiative energy
losses, which occur in the form of bremsstrahlung and posi-
tron annihilation, transfer energy back to photons and lead to
the coupling of the electron and photon radiation fields. One
therefore speaks of coupled electron-photon showers.
The electron-photon macroscopic radiation field can be
described mathematically by a coupled set of integrodiffer-
ential transport equations. These transport equations are pro-
hibitively complicated thereby excluding an analytical treat-
ment except under severe approximations. The MC
technique is a solution method that can be applied for any
energy range and underlying geometry and material compo-
sition.
A solution of the transport problem of particles in matter,
which is exact within the existing knowledge of the elemen-
tary collision processes, can be obtained by an analog MC
simulation. In an analog simulation all particle interactions
with surrounding atoms and molecules are explicitly simu-
lated, including those of secondary particles created in the
collisions. An analog MC technique is therefore a faithful
simulation of physical reality on a digital computer: particles
photons for example are “born” according to distributions
describing the source, they travel a certain distance, deter-
mined by a probability distribution, to the site of a collision,
and scatter into another energy and/or direction state, possi-
bly creating additional particles. These photons eventually
“die” as a result of pair production or photoelectric events or
when they Compton scatter to energies below a predeter-
mined low-energy photon cutoff, often called PCUT. Analog
simulations, often referred to as “event-by-event” or
“interaction-by-interaction” techniques, are typically used
for the transport of neutral particles. The analog simulation
of charged particle transport is not practical, due to the large
number of interactions they undergo until locally absorbed as
the energy of the charged particle falls below the predeter-
mined low-energy limit for tracking charged particles, often
call ECUT. All general purpose MC codes therefore employ
condensed history schemes for charged particle transport,
discussed in more detail in Sec. II B 2.
Within a MC simulation, quantities of interest can be
computed by averaging over a given set of particle showers
also referred to as “histories,” “cases,” “trajectories,” or
“tracks”. One can calculate both observable measurable
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that cannot easily be measured such as the fraction of par-
ticles originating from a certain component of the treatment
head, the dose fraction due to scattered photons, etc. Al-
though there are techniques for scoring quantities at a point
when using Monte Carlo techniques, in treatment planning
applications, it is usual to score quantities dose mainly av-
eraged over some finite volume or voxel. As the voxel size is
increased, for a given statistical uncertainty the total calcu-
lation time will decrease, but the spatial resolution is reduced
see Sec. III D 6 for more discussion. Another important as-
pect of MC calculations is the presence of statistical uncer-
tainties due to the statistical nature of the method, which is
discussed in more detail in Sec. III D 1.
II.B.1. Analog simulations
An analog simulation of particle transport consists of four
main steps:
1 Select the distance to the next interaction.
2 Transport the particle to the interaction site taking into
account geometry constraints.
3 Select the interaction type.
4 Simulate the selected interaction.
Steps 1–4 are repeated until the original particle and all
secondary particles leave the geometry or are locally ab-
sorbed. A particle is considered to be locally absorbed when
its energy falls below a specified threshold energy.
Step 1 is based on the probability, prdr, that a particle
interacts in an interval dr at a distance r from its initial
position
prdr = e−rdr , 1
where  is the linear attenuation coefficient number of in-
teractions per unit length. A random distance r distributed
according to pr can be sampled using the so-called inverse-
transform method, which equates the cumulative probability
of pr with a random number  distributed uniformly be-
tween zero and unity

0
r
prdr = ⇒ r = −
ln1 − 

. 2
Step 2 involves basic ray tracing, which requires a geom-
etry model that can provide the medium and mass density of
a region together with a computation of the distance to the
next geometry boundary along the particle trajectory.
Step 3 is similar to step 1 except that now the probability
distribution function is discrete, i.e., it involves a fixed num-
ber of final states i, corresponding to an interaction of type i.
Suppose that the cross section for interaction of type i is
denoted by i and the total cross section by =i. A direct
application of the inverse-transform method for n interaction
types yields interaction 1 if 1 /, else interaction 2 if 
 1+2 /, else interaction n, if  1+2+ ¯ +n /.
Perhaps the most difficult part is step 4, where one must
sample energy/direction changes from the differential cross
Medical Physics, Vol. 34, No. 12, December 2007section of the selected process. The manuals of the popular
general purpose codes17,32–34 provide details of the methods
employed for the relevant photon interactions.
Based on the above discussion it should be clear that an
analog MC simulation is conceptually quite straightforward.
II.B.2. Condensed history simulations
The condensed history technique was first described com-
prehensively in the pioneering work by Berger.9 It is based
on the observation that the vast majority of electron interac-
tions lead to very small changes in the electron energy and/or
direction. Many such “small-effect” interactions can there-
fore be grouped into relatively few condensed history “steps”
and their cumulative effect taken into account by sampling
energy, direction, and position changes from appropriate dis-
tributions of grouped single interactions, e.g., multiple scat-
tering, stopping power, etc. Berger defined two main classes
of condensed history implementations. In a class I scheme all
collisions are subject to grouping. The effect of secondary
particle creation above specified threshold energies are taken
into account after the fact i.e., independently of the energy
actually lost during the step by setting up and transporting
the appropriate number of secondary particles. In this way
the correlation between large energy losses and secondary
particle creation is lost. In a class II scheme interactions are
divided into “hard” sometimes also referred to as “cata-
strophic” and “soft” collisions. Soft collisions are subject to
grouping as in a class I scheme; hard collisions are explicitly
simulated in an analog manner.
A class II scheme can be described with the same four
basic steps that make up an analog simulation. The two main
differences are that only hard collisions are included and that
step 2 is much more difficult because the particles do not
move on straight lines and because it involves the selection
of energy, direction, and position changes from multiple scat-
tering distributions. It is also frequently necessary to divide
the distance between catastrophic interactions into shorter
condensed history steps to guarantee the accuracy of the
simulation. As in an analog simulation there is a transport
threshold energy. Particle transport thresholds are often the
same as the particle production thresholds dividing hard and
soft collisions, but this is not a necessary condition.
A class II MC simulation is illustrated in Fig. 1. The upper
portion shows a complete electron track including secondary
electrons and photons shown with dashed lines and not in-
cluding their interactions with energies above the hard col-
lision thresholds. The lower portion is a magnified view of
the shaded box. The actual curved path has been simulated
using four condensed history steps. The filled circles and
arrows show the positions and directions at the beginning of
the steps. The shaded area around the electron track indicates
the region where the energy of subthreshold secondary par-
ticles is in reality deposited. If this volume is small compared
to the calculation resolution i.e., voxel size in the case of
radiotherapy calculations, energy deposition can be consid-
ered local and modeled using a restricted stopping power
along the electron track. Note that the initial and final posi-
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fact that a condensed history implementation does not pro-
vide information on how the particle goes from A to B the
curved dashed line connecting A and B is a more realistic
representation of the trajectory than a straight line from A to
B. This becomes important when the scoring grid is not the
same as the underlying geometry grid or when a single con-
densed history step traverses more than one geometrical re-
gion as in some of the fast MC codes specialized for use in
radiotherapy.35–39 This consideration highlights another im-
portant aspect of a condensed history simulation, namely the
way the transport is performed in the vicinity of or across
boundaries between different regions. The EGSnrc code, for
instance, utilizes single scattering i.e., analog simulation
within a certain perpendicular distance from an interface.40
Although this approach is necessary for accurate simulations
of certain types of geometries, it is generally not needed for
typical radiotherapy calculations.
Although the condensed history technique makes use of
practical MC simulations possible, it introduces the step size
as an artificial parameter. Dependencies of the calculated re-
sults on the step size have become known as step-size
artifacts.41 Step-size artifacts were a major factor in the early
years of most general purpose MC codes. Due to significant
theoretical developments in the nineties the condensed his-
tory technique is now well understood.42,43 This has lead to
the development of high accuracy condensed history
implementations40,44 and faster MC codes that can compute
dose distributions with accuracy comparable to traditional
MC packages in a small fraction of the time.35–39,45
With charged particle transport one stops tracking the par-
ticle’s movement at some low-energy cutoff and the choice
of the cutoff can affect the calculation in two important
ways. The higher the value of the cutoff, the faster the cal-
culation; this can improve the calculation speed significantly.
On the other hand, unless great care is taken, stopping at too
high a cutoff energy can distort the dose distribution since
the “stopped” charged particle might have deposited energy
some distance from where its trajectory was terminated.
FIG. 1. Illustration of a class II condensed history scheme for electron trans-
port. The upper portion shows a complete electron track including secondary
electrons and photons shown with dashed lines and not including their
interactions with energies above the hard collision thresholds. The lower
portion is a magnified view of the shaded box.Thus care must be taken in selecting an energy cutoff.
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It is possible to carry out a single MC simulation in which
one starts with the electron exiting from the accelerator
structure, follows it and its descendants e.g., bremsstrahlung
photons, knock-on electrons through the fixed elements of
the head targets or scattering foils, primary collimators,
monitor chambers, flattening filters, etc., the various beam
shaping devices which are patient specific jaws, multileaf
collimator MLC, applicators, cutouts, wedges, compensa-
tors, and finally the patient as specified by a CT or some
other data set. This tracking of the initial particle and all of
its descendants is referred to as a history. As discussed fur-
ther in Sec. III D 1.1, it is important to include all particles
associated with a single initiating electron as part of the same
history.
Due to significant improvements in the efficiency of pho-
ton beam treatment head simulations,46 the speed of the com-
plete simulation is such that it is feasible to consider per-
forming the entire calculation for each patient.47 However,
there have been a variety of strategies for dividing such cal-
culations into several steps. The first step, transporting par-
ticles through the patient-independent elements, can be inef-
ficient without the use of advanced variance reduction
techniques see Sec. II D. This is especially true for photon
beams, since many bremsstrahlung photons generated in the
target will strike the primary collimator and not contribute to
the beam reaching the patient. One approach to improve the
simulation efficiency is to first perform the simulation of the
patient-independent structures and to store what is called a
phase-space file at a plane just below the fixed elements of
the accelerator head see phase-space plane 1 in Fig. 2. The
phase-space file contains phase-space parameters for all par-
ticles as they cross the scoring plane. The phase-space pa-
rameters consist of the energy, position, direction, charge,
FIG. 2. Illustration of the components of a typical Varian linear accelerator
treatment head in photon beam mode. Phase space planes for simulating
patient-dependent and patient-independent structures are also represented.
For other manufacturers, component structures such as the jaws, MLC, etc.
may be in different locations, thereby potentially requiring a change in the
placement of the phase space scoring planes.and possibly other information such as the region/s of cre-
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proach is that this part of the calculation can be reused as
often as necessary. Particles are then transported through the
patient specific collimation system and are either stored in
another phase-space file at the base of the accelerator see
phase-space plane 2 in Fig. 2 or tracked through the patient
in the same simulation. Storing a second phase-space may be
more efficient when open fields e.g., 1010 cm2 fields are
used for treatment, however, more commonly, when MLCs
are used for beam shaping, the latter approach is likely to be
more efficient.
As we will discuss in Sec. III C, the entire phase-space
data for the accelerator may also be generated using beam
modeling virtual source model approaches which do not
require direct MC simulation of the accelerator for each
treatment. One class of virtual source models is based on
characterizing the results of a MC simulation of the accel-
erator head and another class is based solely on measured
beam data such as depth-dose curves, profiles and output
ratios. In either case, the patient-dependent components e.g.,
the MLC are simulated using either explicit transport meth-
ods or approximate transport methods before detailed trans-
port in the patient.
As with conventional planning methods, experimental
verification forms an integral part of the clinical implemen-
tation of a MC dose calculation algorithm. MC algorithms
will benefit from similar experimental verification proce-
dures as conventional systems, and as such should follow the
commissioning procedures detailed in the AAPM TG-53
report48 and other relevant publications.49,50 Experimental
verification in more complex fields and/or heterogeneous ge-
ometries is useful to verify the expected improved accuracy
associated with MC calculations in these situations.
II.D. Variance reduction techniques and efficiency
enhancing methods
The efficiency, epsilon , of a MC calculation is defined
as: =1 /s2T, where s2 is an estimate of the true variance 2
of the quantity of interest and T is the CPU time required to
obtain this variance. Since both Ns2 and T /N are approxi-
mately constant, the efficiency is roughly independent of N,
the number of histories simulated. There are two ways to
improve the efficiency of a given calculation: either decrease
s2 for a given T or decrease T for a given N while not chang-
ing the variance. Techniques which improve the efficiency by
changing the variance for a given N while not biasing the
result i.e., not changing the expectation value which is the
value expected in an infinitely long run are called variance
reduction techniques. Variance reduction techniques often in-
crease the time to simulate a single history and are only
useful if the overall efficiency is improved. A given tech-
nique may increase the efficiency for some quantities being
scored and decrease it for others. In contrast to variance re-
duction techniques, there are a variety of ways to speed up a
given calculation by making an approximation which may or
may not affect the final result in a significant way.
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ary particles are widely used variance reduction techniques
which are especially useful in simulating an accelerator treat-
ment head.23,46 In the various forms of bremsstrahlung split-
ting, each time an electron is about to produce a bremsstrah-
lung secondary, a large number of secondary photons with
lower weights are set in motion, the number possibly de-
pending on a variety of factors related to the likelihood of
them being in the field. If the number of photons created is
selected to minimize those that are not directed toward the
patient plane, then there is a further saving in time. Russian
roulette can be played whenever there is little interest in a
particle resulting from a specific class of events. The low
interest particles are eliminated with a given probability, but
to ensure an unbiased result, the weights of the surviving
particles are increased by the inverse of that probability. A
common example is to play Russian roulette with secondary
electrons created from photon interactions in treatment head
structures. Another variance reduction method, photon forc-
ing, may sometimes be used to enhance the production of
electrons in the air downstream of the accelerator. In a pho-
ton forcing scheme, the parent photon is forced to interact in
a given geometric region and the weights of the resulting
particles are adjusted accordingly to maintain an unbiased
result.
Range rejection and increasing the energy at which elec-
tron histories are terminated energy cutoffs are examples of
methods which, when used correctly, improve efficiency by
decreasing the time per history without significantly chang-
ing the results. In range rejection, an electron’s history is
terminated whenever its residual range is so short that it can-
not escape from the current region or reach the region of
interest. In most implementations this ignores the possible
creation of bremsstrahlung photons while the electron loses
energy which means this is an approximate technique. When
applied to electrons below a certain energy threshold, this
form of range rejection produces the same results in a re-
duced computing time.23 It is also possible to implement
range rejection in a manner which properly accounts for
bremsstrahlung production and thus make it an unbiased
variance reduction technique. By stopping tracking of elec-
trons at a higher energy, efficiency can be improved, but this
may have an effect on the dose distribution if too high a
threshold is used. Playing Russian roulette with particles at
energies below a relatively high transport cutoff or with
range-rejected particles is a comparable variance reduction
technique for reducing the simulation time. However, its
implementation is typically more difficult and this has fa-
vored the use of range rejection and high transport cutoffs in
situations where it is easy to demonstrate that the resulting
error is sufficiently small.
There are other variance reduction and efficiency enhanc-
ing techniques which collectively have allowed substantial
increases in the speed of a calculation. These methods in-
clude the reuse of particle tracks,37 and other adaptations of
particle track reuse, such as the simultaneous transport of
particle sets STOPS approach of Kawrakow,36 which is a
variance reduction technique. For a more comprehensive re-
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niques, readers are referred to a chapter by Rogers and
Bielajew51 and the papers by Rogers et al.23 and Kawrakow
et al.46,52 Other useful references on the influence of variance
reduction methods in the context of phantom and patient
treatment planning are provided in the articles by Ma et al.53
and Kawrakow and Fippel.45
In summary, variance reduction techniques are an impor-
tant requirement for the use of MC calculations in the clini-
cal setting; without them, calculation times would still be too
long for use in most situations. However, inappropriate use
of a variance reduction technique can reduce calculation ef-
ficiency, thus increasing calculation time. In principle vari-
ance reduction techniques, implemented correctly, do not al-
ter the physics and thereby produce unbiased results. Other
efficiency improving techniques can significantly alter the
accuracy of the calculation if applied inappropriately. Im-
proper implementations can lead to unpredictable results in
either case.
It is incumbent upon the medical physicist to understand,
at a minimum, those techniques that the user can adjust in a
clinical MC algorithm. In addition, tests must be done to
show correct implementation of those techniques over the
range of clinical situations. Vendors should provide adequate
documentation for users to understand the techniques em-
ployed and how the implementation was validated.
III. MONTE CARLO SIMULATION OF RADIATION
TRANSPORT IN ACCELERATORS AND
PATIENTS
III.A. Review of current Monte Carlo codes
A large number of general purpose MC algorithms have
been developed for simulating the transport of electrons and
photons. Perhaps the most widely used of these in medical
physics is the EGS code system.12,16,17,40,44 There are several
other comparable general purpose systems used in medical
physics such as the ITS Refs. 54 and 55 and MCNP
systems11,32 both of which have incorporated the electron
transport algorithms from ETRAN Refs. 10 and 56 which
was developed at NIST by Berger and Seltzer following the
condensed history techniques proposed by Berger.9 Other
newer general purpose systems include PENELOPE Ref. 34
and GEANT4.33 The EGS and ITS/ETRAN and MCNP systems are
roughly of the same efficiency for calculations in very simple
geometries when no variance reduction techniques are used,
whereas the other systems tend to be considerably slower. An
important special purpose code is the EGS user code,
BEAM.23,57–60 The BEAM code is optimized to simulate the
treatment head of radiotherapy accelerators and includes a
number of variance reduction techniques to enhance the ef-
ficiency of the simulation.46 Comprehensive reviews of MC
simulation of radiotherapy beams from linear accelerators
are available elsewhere.24,25
While the accuracy of these general-purpose codes can be
roughly the same as long as they are carefully used, these
codes are considered too slow for routine treatment planning
purposes. Several groups have published on the use of par-
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provide more reasonable turn-around times for simulation in
clinical research.61–63 Specific to radiation therapy, there
have been a variety of MC codes developed to improve the
calculation efficiency, especially in the patient simulation.
The PEREGRINE system North American Scientific: Nomos
Division was developed at the Lawrence Livermore Na-
tional Laboratory and has been benchmarked against
measurements.27 The PEREGRINE electron transport algorithm
is a modified version of the EGS4 condensed history imple-
mentation. PEREGRINE uses the random hinge approach64 for
electron transport mechanics. Several efficiency enhancing
and variance reduction techniques are implemented in PER-
EGRINE, including source particle reuse, range rejection, Rus-
sian roulette and photon splitting. Parallelizing the calcula-
tion on several computer processors is also implemented to
reduce the overall dose calculation time. The system de-
couples the scoring zones from the transport geometry.
Source modeling in PEREGRINE is achieved by performing a
full MC simulation of the accelerator head using the BEAM
code23 and using the output to create a source model65 from
which source particles are regenerated above the patient-
dependent beam modifiers. PEREGRINE uses several approxi-
mations when transporting the beam through the patient spe-
cific beam modifiers, followed by transport through a
patient’s CT data set.66 The PEREGRINE system was the first
MC algorithm to receive FDA 510-K approval and repre-
sents the first commercially available photon beam treatment
planning system in the United States.
Several commercial MC implementations currently avail-
able or under development are based on the Voxel Monte
Carlo VMC series of codes. The initial version37 of VMC was
only applicable to electron beams and involved several ap-
proximations in the modeling of the underlying interaction
processes. Improved treatment of multiple elastic scattering67
was incorporated in 1996, PENELOPE’s random hinge method
in 1997,68 and all remaining approximations removed in
2000.45 A photon transport algorithm was added in 1998,35
which included precalculated interaction densities in each
voxel similar to approaches developed previously.69,70 The
resulting code was named XVMC. In 1999, a series of ad-
vanced variance reduction techniques were developed and
incorporated into XVMC which brought an additional factor
of 5–9 increase in simulation speed. Treatment planning ap-
plications and experimental verification of VMC-based sys-
tems have been reported in several articles.71–75 Separate ver-
sions of the VMC code were subsequently developed by
Fippel XVMC Refs. 45 and 76 and Kawrakow VMC++36.
XVMC is being incorporated into the Monaco CMS, Pre-
cisePlan Elekta, and iPlan BrainLab treatment planning
systems. VMC++ includes additional refinements in the phys-
ics models, such as the exact Kawrakow–Bielajew multiple
scattering formalism,77 including relativistic spin effects,17
and the STOPS method mentioned in Sec. II D. VMC++ is
the basis for the first commercial electron MC algorithm
from Nucletron and is being incorporated into the Master-
plan Nucletron and Eclipse Varian treatment planning
systems for photon beam dose calculations. The VMC/XVMC/
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MC-based research systems including those at the University
of Tubingen, McGill University, and the Virginia Common-
wealth University.
Another MC code that has reached commercial imple-
mentation is the Macro Monte Carlo MMC method38,78 for
electron beam treatment planning. MMC uses the MC tech-
nique, but is very different from the standard simulation of
radiation transport. MMC uses a precalculated database from
EGSnrc simulations of electron transport through small
spheres of varying sizes and materials and follows a random
walk through the CT phantom based on these precalculated
values. The commercial implementation of MMC, eMC,
Eclipse, Varian makes use of some precalculated
accelerator-specific information; however, fluence intensities
arising from the various subsources are fitted to the user’s
measured data.79 More details on the performance of the
eMC system for clinical electron dose calculations is avail-
able elsewhere.80
There are several institutions currently engaged in devel-
oping MC radiotherapy applications for clinical and/or re-
search related purposes. MCDOSE Ref. 53 and 81 is among
the first of these types of systems. MCDOSE is based on EGS4
and includes fundamental changes in some aspects of the
electron transport in order to improve speed. MCDOSE has
been shown to give results very similar to EGS4.53 It performs
particle tracking through the beam modifiers in conjunction
with the patient calculation and has built-in capability to
handle various models of the incident beam. The speed ups
have been obtained by using various techniques bremsstrah-
lung splitting, photon forcing, track repetition,37 and range
rejection.
The MCV Monte Carlo Vista 82 code is used for clinical
IMRT planning and verification61 as well as for a variety of
research related applications. MCV interfaces photon-electron
MC dose algorithms to the Pinnacle Philips Radiation On-
cology Systems, Madison, WI commercial planning system,
and calculations are performed in a parallel environment us-
ing multiple Unix-based processors.82 Treatment head simu-
lation is accomplished using a modified version of the BEAM
code, with calculations divided into two stages, based on the
patient-dependent83 and patient-independent component
structures.82 Patient and phantom calculations within MCV
are completed using DOSXYZnrc,58 VMC++ described
above, or MCVRTP, a C++ MC code developed by Philips
that uses many of the algorithms of EGS4.82 MCV utilizes
variance reduction techniques inherent to the subcodes it
uses, and achieves speed by use of multiple processors.82
Another major research code is the dose planning
method39 DPM code system developed initially for perform-
ing electron beam dose calculations in a voxelized geometry.
DPM utilizes the Kawrakow–Bielajew multiple scattering
formalism77 and the random hinge approach for transport
mechanics.64 Particles do not stop at boundaries39 as is the
case with other fast codes. DPM has been integrated into the
University of Michigan’s in-house treatment planning system
UMPlan and is currently being used for a variety of photon
84,85beam treatment planning studies.
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Ref. 86 has been in use for treatment planning research at
UCLA. There have been a series of publications related to
the use of RT_MCNP for a variety of applications, from radio-
surgery to IMRT planning using a micromultileaf
collimator.86–91 Finally, treatment planning studies using the
GEANT,92–94 PENELOPE,95 gamma electron positron transport
system GEPTS,96,97 and ORANGE Ref. 98 MCNP-based
MC codes have also been reported.
In an effort to quantify the speed and accuracy for the
phantom component of the calculations by the various MC
codes being used for research and/or clinical planning pur-
poses, Rogers and Mohan99 proposed what came to be
known as the ICCR benchmark. The tests and geometries for
the ICCR benchmark comparisons were as follows:99 a
speed test: phantom of dimensions 30.530.530 cm with
5 mm3 voxels filled either randomly with one of 4 materi-
als water, aluminum, lung, and graphite or with water
alone, 6 MV photons spectrum from a point source at 100
cm SSD and collimated to 1010 cm2 at the phantom sur-
face, b accuracy test: heterogeneous phantom as defined in
a with 552 mm voxels 2 mm along the depth axis,
18 MV photons spectrum from a point source at 100 cm
SSD and collimated to 1.51.5 cm2 at the phantom surface.
Beam spectra268 were provided for these comparisons in or-
der to standardize the beam model used in the dose calcula-
tions. Statistical uncertainties were to be reported as the rela-
tive uncertainty in the dose for voxels with a dose greater
than some arbitrary lower limit, such as 50% of the maxi-
mum dose.99 Results for the ICCR benchmark are summa-
rized in Table I. Some timing results have been added re-
cently. Timing values have been scaled to that on a single
Intel P-IV 3.0 GHz processor.
The reader should be aware that the timing results re-
ported in Table I are susceptible to large variations on the
order of at least 20% due to variations in compilers,
memory size, cache, etc.99 Timing comparisons for more
clinically relevant treatment plans are presented in Sec.
III E 4. These results have been reported by medical physi-
cists using commercial MC systems for treatment planning.
III.B. Accelerator treatment head simulation
III.B.1. Sensitivity of simulations to electron beam
and other parameters
In general one does not know all the details of the clinical
accelerator. For example, the characteristics of the incident
electron beam are only known approximately. Knowledge of
the sensitivity of MC simulation results to input parameters,
such as the position, direction, and energy of the initial elec-
tron beam exiting the accelerator and to details of the geom-
etry of the treatment head, is important. A sensitivity analysis
is indispensable in determining which source and geometry
parameters to adjust and by how much in order to improve
agreement with user-specific measurements.
Factors influencing the characteristics of a photon beam
are the energy, spatial, and angular distributions of the elec-
trons incident on the target or exiting the waveguide, and
4827 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4827the dimensions, materials, and densities of all the compo-
nents interacting with the beam the target, primary collima-
tor, flattening filters, monitor chamber, collimating devices,
such as blocks or MLCs, and beam modifying devices such
as wedges. Several investigators have reported on the sen-
sitivity of megavoltage beam simulations to the electron
beam striking the target and other treatment head
parameters.19,100–103 Faddegon et al.,19 in simulating Siemens
accelerators, showed that the key parameters are the mean
energy and focal spot size of the electron beam incident on
the exit window, the material composition and thickness pro-
file of the exit window, target, flattening filter, primary col-
limator, and the position of the primary collimator relative to
the target. Bieda et al.101 showed that the accelerator simu-
lation for 20 MeV Varian-produced electron beams was
very sensitive to the distance between the scattering foils
and, to a lesser extent, to the width of the shaped secondary
scattering foil. Changes to the primary or secondary foil
thickness were found to significantly alter the falloff and
bremsstrahlung components of the depth-dose curve.101
Sheikh-Bagheri and Rogers102 performed calculations of “in-
air” off-axis ratios and depth-dose curves and compared
these with measurements to derive estimates for the param-
eters of the electron beam incident on the target, and to study
the effects of some mechanical parameters, such as target
width, primary collimator opening, flattening filter material,
102
TABLE I. Summary of timing and accuracy results
performed using 6 MV photons, 1010 cm2 field si
and a 1.51.5 cm2 field size, as detailed in the ICC
time it would take running on a single, Pentium IV, 3
results, as well as the method used to scale the time
compilers, memory size, cache size, etc.
Monte Carlo code Time estimate
min
ESG4/PRESTA/DOSXYZ 43
VMC++ 0.9
XVMC 1.1a
MCDOSE modified ESG4/PRESTA 1.6
MCV modified ESG4/PRESTA 22
DPM modified DPM 7.3b
MCNPX 60c
PEREGRINE 43d
GEANT4 4.6.1 193e
aResults not originally part of the ICCR benchmark
bResults not originally part of the ICCR benchmar
modified version of DPM developed for clinical plan
cTiming results not originally part of the ICCR be
Calculations were performed using the *F8 energy d
dTiming and accuracy results not originally part of
author D.S.-B.
eTiming and accuracy results not originally part of
author Seuntjens based on Poon and Verhaegen Ref.
Timing results are for the standard physics model; th
2 more CPU time. The accuracy result reported is de
Verhaegen Ref. 94, applies to 1.25 MeV monoen
EGSnrc using PRESTA-II electron step algorithm and
1.25 MeV photons, the maximum difference with EGand density. Their study included several different photon
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manufacturers Varian, Siemens, and Elekta. The electron
beam radial intensity distribution was found to influence the
off-axis ratios to a great extent. The greater the width of the
electron-beam radial intensity distribution, the relatively
more intense is the photon beam on the central axis.102 Fig-
ure 3 shows the influence of the electron-on-target energy
and radial intensity FWHM on 4040 cm2 field profile
doses from Tzedakis et al.103 The calculated profiles are ob-
served to be quite sensitive to these parameters. The central
axis depth dose curves are also strongly influenced by the
electron-on-target energy.102 However, the central-axis
depth-dose curves are quite insensitive to variation in the
radial intensity distribution of the electron beam striking the
target, because the dose along the central axis is deposited
primarily by particles in the vicinity of the central axis. The
divergence of the electron beam incident on the target also
needs to be considered as it may affect large field profiles.
Regarding the influence of individual treatment head
components, Sheikh–Bagheri and Rogers102 see Table II
showed that even small changes 0.01 cm in the primary
collimator’s upstream opening can affect in-air off-axis ratios
by restricting the number of bremsstrahlung photons contrib-
uting to the scattered photon fluence reaching off-axis points
downstream. Dose profiles are quite sensitive to the compo-
sition and density of the flattening filter as noted in Fig. 4,
the ICCR benchmark. Timing comparisons were
d those for the accuracy test, using 18 MV photons
chmark Ref. 99. All times have been scaled to the
processor. Readers should be aware that the timing
subject to large uncertainties due to differences in
mean difference relative to ESG4/PRESTA/DOSXYZ
0, benchmark calculation
±1
±1
±1
±1
±1
aximum difference of 8% at Al/lung interface
n average ±1% agreement
±1
1 for homogeneous water and water/air interfaces
, from Ref. 76.
dy, reported independently by author I.J.C. for the
calculations.
ark study, reported independently by author J.J.D.
ition tally.
ICCR benchmark study, reported independently by
CR benchmark study. Estimated independently by
d ICCR type speed-test dose calculations Ref. 270.
-energy and the PENELOPE model lead to a factor of
from the interface perturbation studies in Poon and
c photon beams and represents the difference with
t” boundary crossing. For a water/Pb interface and
increases to 6% Ref. 94.from
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etry and materials within the MC code is an important con-
sideration. This includes verification of the input of the com-
ponent geometric specifications, for example, by using the
listing files available with the BEAM Ref. 23 system. More-
over, for complicated components, such as the flattening fil-
ter, independent attenuation calculations of these structures,
using monoenergetic photons, may be helpful to verify their
thickness profiles.105,106 Attenuation of the photon beam by
the monitor ion chamber and the field mirror is negligible
and these structures are often omitted from MC simulations
FIG. 3. a The lateral dose-profile curves as a function of the FWHM of the
radial intensity distribution for a monoenergetic, 6 MV, electron beam. The
measured profile and five calculated dose profile curves are presented; each
curve is normalized to the central axis. b The influence of electron energy
on dose-profile curves. The energy was varied from monoenergetic 5.4 to
6.6 MeV. For clarity only four calculated and measured profiles are pre-
sented; each curve is normalized to the central axis. The FWHM of the
radial intensity distribution was 0.3 cm FWHM in all cases. Reprinted from
Tzedakis et al. Ref. 103 with permission.of photon beams, except when backscatter to the monitor
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mirror are, however, potentially important structures in elec-
tron beam simulations. The collimating jaws have no signifi-
cant effect on the energy and angular photon
distributions.14,107,108 Changing the composition of the sec-
ondary collimators from pure tungsten to an alloy containing
50% tungsten by weight does not significantly affect the cal-
culated dose.102
Even in those cases for which the beam model includes an
explicit simulation of the accelerator head, end users of MC
treatment planning algorithms will probably have little con-
trol over parameters affecting the treatment head simulation.
It will be incumbent upon vendors to provide accurate beam
models verified by measurements for treatment planning
purposes. Vendors and developers should be aware of poten-
tial difficulties associated with accurate specification of the
treatment head component structures. Such issues include
difficulty in obtaining proprietary information from accelera-
tor manufacturers, incorrect proprietary information pro-
vided by the manufacturers,101,102,104 undocumented accel-
erator updates, and large uncertainties in important
parameters needed for accurate simulation, such as the
electron-on-target energy. Accelerator vendors are encour-
aged to make accurate, detailed information of their accel-
erators accessible in formats easy to implement in MC simu-
lation, as established for instance by Siemens.109
III.B.2. Electron beam specifics
Simulation of the passage of electron beams through the
treatment heads of accelerators has figured prominently in
MC radiotherapy calculations for many years. The first ap-
plication of the BEAM code23 was to simulate electron beams
for a wide range of accelerators. A variety of publications
have demonstrated the accuracy of this technique for com-
puting dose distributions and output ratios.24,110,111 Recent
work has established the methodology to achieve high accu-
racy in matching calculated and measured dose distributions
for even the largest fields, including asymmetries and the
bremsstrahlung tail.112
The procedure for simulating the electron beam treatment
head is quite similar to that of x rays. The components gen-
erally important for electron beam therapy treatment head
simulations are shown in Table III. Photon beam components
are also presented for comparison. For electrons, accelerators
from the major vendors use a pair of scattering foils to flatten
the beam with minimal bremsstrahlung contamination. A
low-scatter monitor chamber may be employed and the mir-
ror may be retracted from the beam. The jaw position is
generally fixed for a given applicator and energy such that
the relative output ratio depends only on the custom insert.
The critical parameters for electron beam simulation are
different than those for x rays. Sensitivity analyses provide
quantitative evidence of these differences.100,101,113 Due to
the sensitivity of the beam range to the primary electron
energy a 0.2 MeV change in electron energy corresponds
with a 1 mm change in beam range, the incident electron
energy is the primary tuning parameter for electron beam
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tive to all the materials in the beam, especially the scattering
foils and may also be affected by the monitor chamber if it
has thick walls. Hence, accurate geometric descriptions of all
components in the beam path are required for the simulation
of electron beams. Asymmetries are evident in electron dose
TABLE II. A summary of the findings of Sheikh-Bagheri and Rogers Ref. 1
Parameter in the linac model Impact on i
Mean energy of the incident electron intensity
distribution assumed Gaussian
Decrease with increasin
e.g., −0.105±0.007 /MeV
Siemens KD 6 MV beam
change produces an ob
Gaussian width of the incident electron
energy distribution
Show little or no depen
FWHM from 0% to 20%
Siemens KD 6 MV beam
distribution has a small
Gaussian with 14% FW
3% FWHM on the RHS
2% for a Siemens KD 1
Gaussian width of the incident electron radial
intensity distribution
Decrease quadratically
width, e.g., a change in
leads to 7% decrease at
MV beam.
Divergence of the incident electron beam
at a given intensity distribution FWHM
Show little or no effect
decrease of 1% at 15 cm
an 18 MV Varian beam.
Radius of the upstream opening of the primary
collimator
Sensitive to small chan
opening by 0.01 cm pro
off-axis for a Varian 18
Density and material of the flattening filter Show strong dependen
density by 1 g cm−3 cau
off axis for a Varian 15
material has a very lar
the density change.
FIG. 4. MC calculated profiles in a water phantom modified DPM, Univer-
sity of Michigan/UMPlan for a 15 MV 1010 cm2 at 10 cm depth in
water. Input for the profile calculations were the phase space simulations of
the Varian 21-EX treatment head, performed using BEAMnrc, with two
different material compositions specified for the flattening filter. Open
circles represent the MC profile with a copper flattening filter 	
=8.933 g /cm3 and open triangles that with the tungsten filter 	
=19.30 g /cm3. Ion chamber measurements are shown in the solid line.
Calculations and measurements are each normalized to the central axis Ref.
104.
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incident beam and the lateral position of shaped scattering
foils and the monitor chamber.
III.C. Modeling of the linear accelerator treatment
head
III.C.1. General schemes
A beam model in the context of MC treatment planning is
any algorithm that delivers the location, direction, and en-
ergy of particles to the patient dose-calculating algorithm.
The direct MC simulation of a beam is one form of a beam
model but for clarity we refer to it as a beam simulation
rather than as a beam model. Accurate beam modeling is an
important prerequisite for accurate dose calculation within
the patient. Beam models use one of three possible ap-
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TABLE III. Components in the treatment head and other beam modifying
devices for x ray and electron beams.
X rays Electrons
Exit window and target Exit window and primary scattering foil
Primary collimator Primary collimator
Flattening filter Secondary scattering foil may be present
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4830 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4830proaches see Fig. 5: i direct use of phase-space informa-
tion from the accelerator treatment head simulation, ii de-
velopment of virtual, multiple-source models reconstructed
from the treatment head simulation with or without enhance-
ment from measurements, or iii development of other mod-
els derived exclusively from measurements measurement-
driven models.
While the utilization of direct phase-space information
provides details on the physical interactions within the treat-
ment head, it may not be practical for routine clinical
application.65,93,114–116 Some of the limitations include: a
generation and quality assurance of phase-space information
requires MC simulation expertise, b accurate phase-space
simulation is dependent upon accurate input parameters
such as the incident electron energy as well as detailed
geometric and material specifications of the accelerator com-
ponents, which may be subject to inaccuracies, as well as
proprietary issues, c storage requirements are large—
typical MC simulation may require up to 109 phase-space
particles for multiple photon beams,115 which may amount to
tens or hundreds of gigabytes of computer disk space for an
accelerator with two photon energies and five electron ener-
gies with five different applicator sizes,117 and d due to the
much slower pace of speed increase in hard drives and net-
works compared to CPU speed development, reading the
phase-space data can be a bottleneck in the calculation. It is
therefore clear that a more concise, accurate characterization
of radiation interactions in the treatment head is necessary
for performing routine clinical MC dose calculation.
FIG. 5. The three “routes” for accelerator beam model specification: a
solid line—direct use of phase-space information from simulation of the
accelerator treatment head, b dashed line—multiple virtual source mod-
els derived from the phase-space information with or without enhancements
from measured data, and c dotted line—development of other models de-
rived from measurements measurement-driven models.Another method for beam model specification, initially
Medical Physics, Vol. 34, No. 12, December 2007proposed by Ma et al.,114 is based on the development of
multiple-source models with parameters derived from the
original simulated phase-space data.65,88,93,114,116–120 In a
multiple-source model, source particles are grouped by the
location of their last interaction prior to being scored at the
phase-space plane, resulting in subsources representing the
major components of the treatment head. Fluence distribu-
tions for each subsource may be reconstructed from the
phase-space data in the form of correlated histogram
distributions,65,93,114 thereby approximately retaining correla-
tion of the particle’s position, energy and direction. Although
the development of accurate multiple-source models is also
reliant upon simulation parameters and geometric and mate-
rial specifications of the component structures, sub-sources
may be “adjusted” without redoing the simulations, based
on measurements to optimize agreement between calcula-
tions and measured data, An example of such an approach
consists of adjusting the spatial or energy boundaries of the
planar fluence and energy distributions for each subsource to
produce agreement with measured dose profiles and depth-
dose curves, respectively, for a range of square field shapes,
starting with fluence distributions reconstructed from phase-
space data for one field size.117,121 For instance, one changes
the range of energies sampled from the discrete energy dis-
tribution as a function of radius, to provide a match with
measurements, without having to redo the entire treatment
head simulation. This method has been extended to MC-
based commissioning of electron beams.111,121 Models devel-
oped for reference accelerators were used to accurately com-
mission within 2% /2 mm of measurements in the high
dose/high gradient profile regions electron beams from other
machines of similar design by adjusting a few parameters in
the model. Implementation of photon and electron beam
multiple-source models has been reported for a variety of
accelerator manufacturers including, Varian,122,123
Siemens,73,124,125 Elekta,73,86,88 Novalis BrainLab,87,89 and
Cyberknife.126
A possibly more practical approach to beam modeling in-
volves derivation of the model parameters from a standard
set of measurements. The advantage of such measurement-
driven models is that they may be developed without depen-
dence on the details of the accelerator treatment head. Flu-
ence distributions in measurement-driven models may be
developed starting with analytical models whose parameters
are optimized based on minimization of the differences be-
tween calculations and measurements.100,125,127–131 Informa-
tion for the model can be deconvolved from measured
data.100,127 Similar methods have been reported for beam-
model specification using conventional dose calculation al-
gorithms with good agreement established between calcula-
tions and measurements in water phantoms.132–135 The same
beam modeling criteria for conventional dose algorithms
should also be applicable to the MC method although differ-
ences in the technical details such as source parameterization
and software implementation are expected. The use of
measurement-driven beam models eliminates the need for
phase-space simulation and, as the model parameters are de-
rived from measurements, may provide an added level of
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phantoms. Moreover, specification of beam models is similar
to that with conventional dose algorithms, and does not re-
quire expertise with MC accelerator simulation. However,
rigorous verification of measurement-driven models in het-
erogeneous phantoms is necessary to validate the empiri-
cally derived fluence distributions. It has been shown that,
in addition to the use of measurements in water phantoms,
test cases in heterogeneous phantoms under conditions of
electronic disequilibrium may be necessary to determine the
correct energy spectrum unambiguously.136
III.C.2. Patient-specific beam modifiers
Transport through the patient-dependent components
such as the field-defining collimators and the MLC may be
classified into one of the following three schemes, which we
will term: a explicit transport, b explicit-approximate
transport, and c pseudo-explicit transport. In an explicit
transport scheme, all particles with appropriate energy cut-
off values are transported using MC techniques through the
components; all details of the design geometry such as
rounded leaf ends, interleaf spacing, etc. for a MLC should
be included in the geometry modeling.72,115,137 With explicit-
approximate transport, approximations are employed in the
MC photon/electron tracking scheme to improve the effi-
ciency of the calculation.83,87,138,139 An example is the ap-
proach of Siebers et al.,83 in which only first Compton scat-
tered photons are transported through the MLC. The method
of Tyagi et al.139 includes simulation through the detailed
MLC geometry accounting for all Compton scattered pho-
tons, however, ignores the secondary electrons, i.e., assumes
they deposit their energies locally. In a pseudo-explicit trans-
port scheme, beam fluence distributions are reconstructed
from the phase-space simulation to develop subsources for
characterizing components, such as the field defining
jaws,93,120 electron applicators,114 and the MLC.88 Although
the need for time-intensive, explicit transport is obviated
with the use of multiple subsources, the ability to incorporate
detailed geometric characteristics of components like the
MLC may be difficult with this approach. Appropriate
benchmarking must be performed by developers and vendors
to evaluate the tradeoffs between speed and accuracy related
to the use of various beam model approaches in MC-based
modeling of patient-specific beam modifiers.
III.C.3. Output ratios
The output ratio or relative output factor is the ratio of
dose per monitor unit in a phantom for an arbitrary field size
to that for a reference collimator setting, the latter usually
1010 cm2 at a SAD or SSD of 100 cm for a depth of 10
cm for x-ray beams.140 Output ratios over the range of clini-
cally useful field sizes are heavily influenced by the amount
of head scattered radiation impinging on the phantom.140,141
Radiation generated by clinical accelerators can be charac-
terized by a primary photon source generated through the
bremsstrahlung process, and other extrafocal sources ac-
counting for scattered photons arising primarily from the
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the energy fluence in a 1010 cm2 field. The primary
source is a narrow sharp source normally a few millimeters
in diameter, while the extrafocal sources tend to be much
broader, more diffuse and bell-shaped in nature.142,143 The
output ratio is affected by the size and geometry of these
sources. The collimators jaws and MLCs block the extrafo-
cal source when the field size is sufficiently small 
3
3 cm2 and for smaller fields the primary source starts
being blocked by the collimators. The combination of ex-
trafocal source and primary source cutoffs cause the output
ratios to fall off sharply at small field sizes.143,144 Accurate
source modeling of small fields is especially important in
IMRT planning where multiple, small field, off-axis seg-
ments are often used.61,87,145 For medium sized fields 10
10 cm2–2020 cm2, output ratios are more likely af-
fected by the extrafocal sources as the collimators are large
enough to expose the entire primary source, however, small
enough to eclipse the extrafocal sources. In large fields, be-
yond 2020 cm2, the extrafocal sources are nearly com-
pletely exposed—the increase in output ratios in these situa-
tions is primarily a result of phantom scatter, lack of
backscatter from the collimator jaws to the monitor chamber,
and stray radiation from the treatment head.146,147 Depending
on the location of the jaws relative to the transmission cham-
ber which varies among the different linear accelerator
types, radiation backscattered from the jaws into the cham-
ber can also have an effect on the output ratios. Relative to
large field sizes 4040 cm2, backscattered radiation in-
creases by 2%−3% at small field sizes 33 cm2 for 15
MV photons on a Varian 21EX linear accelerator, for ex-
ample. Studies for photon beam MC algorithms have shown
calculated output ratios to be within 1.5% of measurements
over a range of field sizes when accounting for backscattered
radiation.27,139,148,149 MC calculated electron beam output ra-
tios for field size-specific applicators have also been re-
ported to agree with measurements within 1%–2%.26,110
III.C.4. Dose buildup
There has been considerable discussion on discrepancies
between MC calculations and measurements in the dose
buildup region. Hartmann-Siantar et al.27 observed MC dose
deficits of up to 5 mm distance-to-agreement versus mea-
surements and attributed these discrepancies to a source of
electrons in the accelerator head not fully accounted for in
the treatment head simulation with BEAM. It has been shown
that arbitrarily increasing the electron contamination by a
significant amount removes the discrepancy.27,88,125 As the
result of further investigation, Ding150 concluded that the dis-
crepancy could not be explained by the electron source hy-
pothesis and postulated that contaminant neutrons emerging
from the treatment head might be the cause. However, Ding
et al.151 subsequently refuted this neutron hypothesis by
measuring minimal neutron component in the dose buildup
region. Abdel-Rahman et al.,152 who performed MC calcula-
tions using EGSnrc and a comprehensive set of measure-
ments with multiple detectors, again found significant differ-
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region for 18 MV photons even when completely simulating
the response of the detectors. They ruled out the following
possible causes of the discrepancy: a an unknown electron
source in the accelerator head simulation, b contaminating
neutrons, c inaccurate cross section data, and d gamma,
p reactions. They also showed that explicit modeling of trip-
let production interactions influences the dose buildup for an
18 MV beam. However, work by Kawrakow153 showed that
a more accurate triplet production model does not remove
the discrepancies. Benchmarking of the NRCC accelerator
photon beams has shown agreement well within 1%, for field
sizes up to 1010 cm2, at all depths154; it should be noted
that the NRCC accelerator 20 MV photons uses a sweeping
beam technique154 as opposed to a flattening filter to flatten
the beam. These comparisons explicitly accounted for
stopping-power ratio variation with depth.
More recently, Kawrakow,155 in performing detailed ion
chamber simulations using the EGSnrc code system, showed
that the relationship between measured ionization and dose
for relative photon beam dosimetry depends on details of the
chamber design, including cavity length, mass density of the
wall material, size of the central electrode, and cavity radius,
in addition to the beam quality and field size. When the
correct ionization-to-dose relationship was used with the ex-
perimental data155 and a variety of other improvements in the
head simulations were made e.g., using a larger diameter
primary collimator opening and including the effects of extra
shielding upstream of the jaws or MLC,156 correcting a bug
in the JAWS component of the BEAMnrc code, including an
angular spread in the incident electron beam and several
small effects in the simulation153, the discrepancies in the
build-up region were reduced to an acceptable level. Chibani
and Ma showed that resolving inaccuracies in the modeling
of the primary collimator for a Varian 18 MV accelerator as
well as including virtual sources for the lead shield and mir-
ror frame, resulted in significantly better agreement between
calculations and measurements in the dose buildup region.156
Other sources of inaccuracy associated with detectors for
dose buildup measurements are presented in Sec. III E 3.3.
III.D. Treatment planning: MC-based patient
calculations
III.D.1. Statistical uncertainties
III.D.1.a. Latent variance and statistical estimators. For
a finite number of independent simulated histories N, the
dose calculated using the MC method is subject to statistical
uncertainty. By invoking the central limit theorem,157 one
can show that the statistical uncertainty in dose is propor-
tional to 1 / N, in the limit of infinite large N. There are
generally two sources of statistical uncertainty in MC calcu-
lations of patient dose—those resulting from the simulation
of the accelerator treatment head and those arising from fluc-
tuations in the phantom/patient dose calculation. Sempau et
al.95 coined the term, “latent variance” to describe the uncer-
tainty due to statistical fluctuations in the phase-space as
opposed to the uncertainty due to the random nature of dose
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phase-space file, the statistical uncertainty in the dose calcu-
lated in a phantom by reusing the particles from the phase-
space file i.e., assuming they are independent and ignoring
correlations between them, will approach the finite, latent
variance associated with the phase space data, regardless of
the number of times the phase space is reused. The use of
source models derived from phase space simulation will tend
to smooth out point fluctuations in the phase space.114 How-
ever, if the latent variance is large enough to introduce sys-
tematic bias then this will be propagated in the reconstructed
phase space source model. Beam models derived exclu-
sively from measurements, on the other hand, are analogous
to those generated using conventional analytical
algorithms—latent variance as defined above is not a con-
cern for such models, but other systematic uncertainties in
the beam model will be present. In estimating the statistical
uncertainty in the patient dose calculation, it is necessary to
account for the latent variance from the phase-space calcula-
tion as well as the random uncertainty from the patient cal-
culation. To make this possible in practice, more work is
needed to develop tools to assess the role of latent variance
in patient dose calculations. Should latent variance be a sig-
nificant factor in the total uncertainty, more independent
phase-space particles need to be used in the patient simula-
tions. It must be emphasized that all beam models are subject
to systematic uncertainties, which are analogous to those in-
troduced by the latent variance. For measurement-driven
models, these uncertainties will be related to inaccuracies in
the measurement data. Both types of models are subject to
systematic uncertainties due to inadequacies in the model
itself.
There are two common methods for calculating statistical
uncertainties: the batch method and the history-by-history
method. In the batch method, the estimate of uncertainty
standard error of the mean, sx¯ of a scored quantity, X, is
given by
sx¯ =
i=1n Xi − X¯ 2
nn − 1
, 3a
where n is the number of independent batches, Xi is the
scored quantity such as dose in batch i, and X¯ is the mean
value of X over all the batches. The sample size is therefore
given by the number of batches, where each batch is a cal-
culation of the same quantity carried out with independent
phase-space file inputs and random number sequences. In the
history-by-history method, Xi represents the scored quantity
in history i rather than batch i so that the standard error of
the mean can be recast in a mathematically equivalent form
as follows:
sx¯ =
 1
N − 1
i=1N Xi2
N
−
i=1N Xi
N
	2	 , 3b
where N is the number of primary independent histories, Xi
the contribution to the scored quantity by independent his-
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that the sample size, n, is given by the number of batches. As
n is usually small on the order of ten or less there is statis-
tical fluctuation in the uncertainty itself. Advantages of the
history-by-history method have been detailed elsewhere.158
An important consideration when calculating uncertain-
ties is to take into account the correlation between a primary
particle and all its secondaries, especially in the case of
bremsstrahlung splitting where a large number of photons
may all come from a single electron. Thus, to be strictly
correct, these secondaries must be treated as part of the same
history. If this correlation is not taken into account one can
underestimate the uncertainty in a dose calculation, as the
secondaries will be treated as independent particles thereby
reducing the uncertainty erroneously. Another important case
of correlation is when a single particle is being used several
times as a source particle. In this situation it is important to
recycle the particles, i.e., use them multiple times, all at once
and treat them as part of the same history. If one were to
restart the phase-space file multiple times, one would lose
the correlation between particles which are all part of the
same history. These secondaries would then be treated as
independent particles causing the uncertainty to be underes-
timated. A more comprehensive review of the implications of
recycling and restarting phase-space particles is provided in
the paper by Walters et al.158
III.D.1.b. Influence of statistical uncertainties on dose dis-
tributions. For radiation therapy dose distributions, sDi
Di, where sDi is an estimate of the standard error of the
mean standard deviation / N of the dose in voxel i and Di
is the dose in that voxel.159–161 The fractional or relative
uncertainty in dose, FDi =sDi /Di1 /Di. In other words, the
fractional uncertainty in dose in a voxel decreases as the dose
increases. This relationship provides a useful rule of thumb
when viewing dose distributions since it implies that the rela-
tive uncertainty in the dose in high-dose regions will be
smaller than in low-dose regions, even though the absolute
uncertainty is usually larger.
From Eq. 3b we see that the uncertainty is roughly pro-
portional to 1 / N. Since, the simulation time TN, it can be
seen that achieving absolute precision sD=0 with MC
simulation requires an infinite calculation time. Fortunately,
absolute precision is not required in dose calculation results.
This section concerns the precision required for MC simula-
tion and the impact of a lack of precision on MC dose dis-
tribution quantities.
Radiation therapy dose distributions contain many voxels
in which the dose is computed for example, a cubic volume
with sides of 10 cm contains 15 625 voxels with sides of 0.4
cm. Since the subvolume receiving a therapeutic dose can
be highly variable, a standardized method to specify the sta-
tistical uncertainty for such a distribution is necessary. Al-
though the statistical uncertainty can be specified for a single
voxel in a dose distribution such as that at the isocenter or at
the maximum dose voxel, Dmax, as described below, these
voxels are poor measures for the uncertainty of a MC com-
puted plan. Alternatively, the statistical uncertainty over
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volume, such as the volume receiving greater than X% of the
treatment dose, can be computed from the square root of the
average variance of each constituent voxel. For example, the
fractional uncertainty in the average dose for voxels with
dose values greater than 50% of the maximum dose,
F¯D0.5Dmax as suggested by Kawrakow, and Rogers and
Mohan99 could be used
F¯D0.5Dmax = 1KD0.5Dmax D0.5Dmax 
sDi
Di
	2, 4
where Di is the dose estimate in the ith voxel, sDi is its
uncertainty, and the summation runs over the K voxels with
dose greater than 50% of Dmax. For clarity in communica-
tion, this report recommends that quantities, such as
F¯D0.5Dmax or F
¯
PTV or F¯ PRV for doses to the specific vol-
umes, planning target volume PTV or planning risk volume
PRV, be adopted as a standard method of reporting statis-
tical uncertainties in dose averaged over the relevant volume.
The use of uncertainties to voxels, such as the maximum
dose should be avoided. In situations where doses in single
voxels are important, such as the maximum dose to a “serial”
organ like the spinal cord, users are reminded to also con-
sider the statistical uncertainty of that dose voxel.162 In such
instances, it may be necessary to simulate a large enough
number of histories so that sDi is very small.
162 This will
ensure that the absolute uncertainty in the highest dose voxel
will also be small. The statistical precision required for dose
estimates in single voxels should be decided upon with guid-
ance from the clinician. Users should also note that for a
constant number of source particles, the statistical uncer-
tainty also depends upon the size of the dose voxel. Reduc-
ing the volume to achieve a “point-like” voxel will require
increasing the number of particles simulated to achieve con-
stant statistical precision.
To varying degrees, statistical uncertainties affect all mea-
sures of the dose distribution, including output ratios, iso-
dose profiles, dose-volume histograms, dose response param-
eters such as equivalent uniform dose and TCP/NTCP. In a
uniform dose distribution, the dose metrics most sensitive to
statistical uncertainties are the maximum and minimum dose
voxels. These extreme values are by definition the voxels
that have the greatest deviation from the mean dose. If one
desires a region of uniform dose e.g., within the PTV, that
dose will not be uniform using a MC-based calculation, due
to statistical fluctuations between adjacent dose voxels. The
reported minimum and maximum dose voxels will differ
from the mean of the idealized dose distribution by up to
several standard deviations if many voxels are present in the
distribution.45,163 For example, in a uniform dose distribution
with 15 625 voxels computed with MC algorithms, due to
statistical fluctuations, there is a 63% probability that the
dose in at least one voxel differs from the mean by more than
four standard deviations.45 With regard to dose prescriptions,
the specification of the maximum dose to a single voxel
when there is a desired volume of uniform dose e.g., the
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larly, dose prescription to the minimum dose voxel will result
in an overdose to the relevant volume. Isodose contours are
also sensitive to statistical noise. For well-defined fields,
such as rectangular fields used in beam commissioning, even
1% 1s statistical uncertainty causes observable jitter in iso-
dose contours. For patient fields that have irregular shapes,
the acceptable amount of statistical uncertainty for isodose
viewing is a matter of personal preference and should be
agreed upon by the planner and the physician. It has been
suggested that 2% statistical uncertainty on the Dmax voxel is
adequate for isodose evaluation.160 When viewing statistical
jitter in MC isodose distributions, the physicist should re-
mind observers that overall dose delivery accuracy is limited
to within a few percent; therefore there is uncertainty in the
actual location of an isodose surface even when dose is com-
puted with non-MC algorithms. From this point of view, the
planning team can use MC isodose jitter as a mechanism to
open the dialog on realistic dose uncertainty in actual treat-
ment delivery.
Integrated dose quantities, such as dose volume histo-
grams DVHs are less sensitive to statistical
uncertainty.159–165 DVHs computed with the MC method rep-
resent the actual DVH that computed with a hypothetical
0% statistical uncertainty simulation, convolved with a sta-
tistical uncertainty distribution. With this realization, Sem-
pau and Bielajew159 and Jiang et al.165 reported that the ef-
fect of the “statistical noise” on DVHs could be removed by
deconvolving the uncertainty from the DVH, allowing sub-
stantial decrease in the required number of histories used,
depending on the complexity of the DVH. In general, the
blurring effect due to statistical noise is greatest for steep
DVHs, such as those for PTVs, while shallow DVHs, such as
those for critical structures are less affected.
The sensitivity of quantities such as TCP and NTCP to
statistical noise depends upon the parameters used by the
model164 and on the magnitude of the noise. Kawrakow161
has shown for general dose-based cost functions that the un-
certainty in the cost function decreases more rapidly than the
individual dose uncertainties when the plan is close to opti-
mum as expressed by the cost function. This implies that
during IMRT optimization, where plan updates are based
upon evaluation of such cost functions, larger statistical un-
certainty might be acceptable.
A method to reduce the effect of statistical uncertainties in
MC dose distributions is to postprocess the dose distribution.
These methods have been termed denoising or smoothing
techniques. Various methods related to digital filtering,166,167
wavelet thresholding,168,169 adaptive anisotropic diffusion,170
and denoising based on a minimization problem171 have been
proposed. A detailed comparison of these methods is pre-
sented in the article by El Naqa et al.172 Denoising is an
approximate, efficiency enhancing method i.e., it is not a
variance reduction technique since it can introduce system-
atic bias into the calculation. Nonetheless, denoising tech-
niques are useful as they can reduce the overall systematic
+random uncertainty when the random component de-
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Kawrakow presented a series of tests to evaluate the suitabil-
ity of MC dose distribution denoising algorithms.167 These
tests are based on the fact that one can determine the “cor-
rect” dose distribution by simulating many histories for a
very high precision and then comparing the denoised distri-
bution from a simulation with a much smaller number of
histories to the high precision results. The tests include:
• visual inspection of isodose contours,
• evaluating root-mean-square difference between dose
distributions,
• evaluating the maximum dose difference,
• comparisons of dose-volume histograms with and with-
out denoising, and
• comparing the fraction of voxels failing an x% /y mm
test.
Denoising methods reduce the number of particles and,
hence, the calculation time required to achieve a given un-
certainty by a factor of 3–10. Denoising techniques require
proper validation under the full range of clinical circum-
stances before they are used with MC dose algorithms.
III.D.2. Dose prescriptions and monitor unit
calculation
The stochastic nature of the MC method raises questions
for prescribing dose. It is common clinical practice to pre-
scribe dose to a single voxel or to base the dose prescription
on the maximum or minimum dose voxels. However, as dis-
cussed above Sec. III D 1.2, in an approximately uniform
dose distribution, the outliers the maximum and minimum
dose voxels are subject to the largest statistical fluctuation
and even other single voxel doses may lack the precision for
monitor unit calculations. Standard treatment planning analy-
sis methods using isodose distributions and dose-volume his-
tograms rely on dose averaged over a volume. It is logical to
extend this practice to the prescription of dose, thereby
avoiding precision issues in doses calculated in small vol-
umes. For example, dose may be prescribed to an isodose
surface, to a region of uniform dose averaged over many
voxels about the isocenter, or to a single point on a dose
volume histogram. The practice is emerging to calibrate the
calculated dose distribution by performing a calculation in
the standard geometry where the accelerator is set to deliver
a given dose per monitor unit, e.g., 1 cGy/MU at a given
voxel. In this case, the dose at the calibration point may be
calculated to high precision by averaging over a large num-
ber of voxels in a uniform dose region.
The issue of monitor unit calculations to specific single
voxels within the target volume e.g., the isocenter for rou-
tine clinical planning may be confounded by large statistical
fluctuations in the doses to individual voxels. Although the
treatment planning practice is quickly moving toward
volume-based dose prescriptions, particularly for IMRT plan-
ning, the ability to perform second MU checks for plan veri-
fication purposes is an important component of the standard
practice. Until more efficient solutions are available, MU cal-
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performed with very high precision. That said, this task
group encourages a shift in paradigm from point-based to-
ward volume-based dose prescriptions, which we feel will
soon become the standard method for prescribing doses in
radiotherapy planning. The task group strongly discourages
vendors from using the Dmax or Dmin dose voxels or other
single voxel doses for dose prescription and monitor unit
calculations in their MC-based treatment planning systems.
Current users of MC algorithms are encouraged to find ways
of circumventing point-based dose prescriptions if their sys-
tems are not flexible enough to allow otherwise. To obviate
the concerns of dose prescription based on a single voxel,
one institution author J.E.C., Ottawa Hospital has devel-
oped the following “work around” method for MC-based
electron beam calculations: A dose distribution is calculated
using 100 MU; this dose distribution in absolute terms is
equivalent to a relative isodose distribution normalized to the
standard calibration conditions 1010 applicator, 100 cm
SSD, dmax depth. For dose prescription, the physician
chooses the isodose line that encompasses the target. The
dose prescription point is then positioned on this isodose line
along the central axis of the beam, and the treatment MUs
are determined. A second calculation is performed as a check
of the MUs and the final dose distribution.
For multiple 3D-CRT or IMRT fields, the procedure for
generating monitor units is similar to that for single fields.
For example, a given isodose line such as the 95% line can
be selected for dose prescription and, for a given field, the
dose contribution to a single voxel e.g., the projected field
cax point along this line is determined from the treatment
plan. For a calibrated MC algorithm, the absolute dose con-
tribution from the given field in this voxel on the selected
isodose line will be computed in units of cGy/MU, from
which the monitor units for the beam can be calculated. A
complete formalism for MU calculations for the different
types of treatment deliveries has been provided by Ma et
al.173
III.D.3. CT-to-material conversions
For conventional algorithms, electron densities extracted
from the CT image are used to scale the influence of primary
and, ideally, also secondary radiation interactions. MC algo-
rithms utilize material density and the material atomic com-
position when performing particle transport. The differing
atomic compositions of patient materials e.g., soft tissue,
bone, lung, air result in different cross sections for the vari-
ous radiation interactions. While material compositions can-
not be determined solely from a single energy CT, they can
be indirectly approximated by estimating the mass density
from the electron density followed by assigning a material to
each voxel.37,86,174–176 For some MC codes, explicit material
specification is circumvented by directly relating the CT
Hounsfield HU numbers to material interaction coeffi-
cients, based upon parameterization of materials representa-
tive of the patient,37 for example those tabulated in ICRU
177Report No. 46.
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rials or material interaction coefficients, correspondence
between these quantities must be established during the CT
and treatment planning system commissioning process. To
ensure appropriate material specifications, it may be desir-
able to have several conversion tables, whose selection is
based upon knowledge of the particular patient’s character-
istics. Use of multiple calibration curves reduces the volume
of inappropriate tissues specified in given regions, such as
lung tissue within a prostate gland, however. Although the
importance of exact material specification has been estab-
lished in other studies,178 more work in this area of research
relevant to clinical treatment planning is necessary. Other
information about the patient may also be helpful. For ex-
ample, in a patient with a hip implant, it may be impossible
to distinguish if the implant is titanium, steel, or a composite
based solely on the CT numbers. In this case, material as-
signment based on knowledge of the material implanted in
the patient would be beneficial. A recent evaluation of the
influence of material compositions on dose distributions178
showed dose errors of up to 10% for 6 and 15 MV photons,
and 30% for 18 MeV electrons due to media and/or mass
density misassignment, when comparing dose distributions
between a known phantom and a CT-imaged phantom with
compositions and densities assigned by a conversion process.
The use of conversion techniques based purely on mass den-
sity e.g., assuming the only patient material is water, but
with varying density, as employed in conventional algo-
rithms, is discouraged with MC simulation because most of
these methods ignore dependencies of particle interactions
on the materials, which can lead to notable discrepancies in
high atomic number materials.176
CT number artifacts caused by issues such as beam hard-
ening in the CT scanning process or by high density struc-
tures, such as dental fillings are potentially important in MC
dose calculation. Other artifacts may arise, for example,
when the CT scanner encounters a sharp edge, such as the
surface of a rectangular solid phantom, where a blurred edge
may result after image reconstruction. In one observed case,
the resultant contour showed 3 mm of additional phantom,
causing the MC-calculated percentage depth dose curves to
be shifted 3 mm toward the surface.269 Such issues are of
relevance to both MC- and non-MC-based algorithms and
will need to be taken into consideration in order to perform
accurate dose calculations in the dose buildup region.
As with any dose algorithm, testing should be performed
to evaluate the effect of artifacts on the accuracy of the MC
dose calculation.179,180 It must be emphasized that the accu-
racy of CT-number to material conversions affects all dose
calculation algorithms, both MC- and non-MC-based meth-
ods.
III.D.4. Dose-to-water and dose-to-medium
Historically, radiotherapy dose measurements and calcu-
lations have been performed in, or specified in terms of the
absorbed dose to water Dw. With MC-based algorithms,
4836 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4836particle transport simulations occur in materials representa-
tive of patient media; dose is therefore specified to the pa-
tient medium Dm. For tissues with densities near
1.0 g /cm3, the difference between Dw and Dm for megavolt-
age photon beams is small 1%−2%, however, for higher
density materials, such as cortical bone, the difference can be
as large as 15%,176 since the stopping powers of water and
these higher-density materials differ more significantly.
Therefore, there is a systematic difference between the dose
computed using conventional analytical algorithms and MC
Medical Physics, Vol. 34, No. 12, December 2007simulation. Figure 6 shows the dose and DVH differences
between plans calculated with Dw and Dm for a typical head
and neck IMRT treatment plan.181
To use MC simulation in the current clinical practice so as
to be able to compare Dm with historical Dw results, requires
a conversion of Dm to Dw for dose prescriptions, isodose
coverage, dose-volume histograms, and any other dose re-
lated metrics. In this context, the converted Dw represents the
dose to a small volume of water embedded in the actual
FIG. 6. MC-based MCV system dose-to-medium Dm
and dose-to-water Dw results for a typical head and
neck IMRT treatment plan: a Dm, b Dw, and c
DVH comparison. Reprinted from Dogan et al. Ref.
181 with permission.medium. Whether one should eventually use Dm in place of
4837 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4837Dw directly in clinical prescriptions remains the subject of
debate.182 Arguments in favor of using Dw for dose specifi-
cations include:
• Historical clinical experience has been derived based on
Dw, hence, Dw allows direct compliance with previous
clinical experience and with conventional dose algo-
rithms. Doses reported in clinical trials are based on Dw,
hence, therapeutic and normal tissue tolerance doses are
based on Dw.
• Accelerator and ionization chamber calibration proto-
cols are Dw based.
• Tumor cells embedded within a medium are more
water-like than medium-like, e.g., a tumor cell embed-
ded in a bone matrix.
Arguments in favor of using Dm for dose specification
include:
• Dm or the dose to the tissues of interest is the quantity
inherently computed by MC dose algorithms. This may
be of more clinical relevance than the doses on which
historical clinical experience is based, which are ap-
proximate estimates of the true dose in the first place.
• Converting Dm back to Dw may involve additional com-
plexity and introduce additional dose uncertainty.
• The difference between Dm and Dw for tissue equivalent
materials is rather small and is likely to have minimal
impact in clinical practice.
• It is known that, due to organ and target motion, the
dose actually delivered in the course of a treatment may
be significantly different from the planned dose. Con-
version of Monte Carlo computed doses to Dw may
analogously necessitate discussions on conversion to
“dose to a static patient,” should 4D planning and de-
livery techniques become routinely used in the clinic.183
The conversion of Dm to Dw or vice versa requires an
application of Bragg–Gray cavity theory: Dw=DmS¯ /	m
w
,
where S¯ /	m
w is the unrestricted water-to-medium mass col-
lision stopping power averaged over the energy spectra of
primary electrons at the point of interest. One method to
accomplish this conversion176 is to utilize the fact that for
patient-like materials, S¯ /	m
w is approximately invariant
throughout a photon radiation therapy field within 1%,
hence, S¯ /	m
w can be used as a post-processing step to con-
vert Dm to Dw. However, this requires that a sufficient num-
ber of materials be specified so that the material-dependent
dose conversion approximates a continuous function.184
Rather than postprocessing the dose conversion, one can
multiply the energy deposited by primary and secondary
electrons on each electron energy-loss step by the factor
L /	m
w
, the ratio of the restricted mass collision stopping
powers of water to local medium for the current energy of
the electron. This is done in the MC transport code, thereby
directly obtaining Dw. Alternatively, material interaction data
may be evaluated over continuously parameterized space
with cross sections and stopping powers for specific materi-
35,37
als scaled relative to water. Figure 7 shows a parameter-
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tissue density for different electron beam energies.37 The fit
is shown to be in good agreement with ICRU data177 for
body tissues. The advantage of this approach is that it cir-
cumvents the potential misassignment of media at material
boundaries37 which arises when the human tissue mass den-
sity range is divided into bins representing different tissues,
especially when the number of material bins is small.184
Until further studies indicate clinical justification for se-
lecting Dm or Dw, it is the consensus of this task group that
MC dose results should: a explicitly indicate the material to
which the dose is computed and b allow conversion be-
tween Dm and Dw using one of the methods discussed above,
or other methods as developed in future investigations.
III.D.5. IMRT dose calculation and optimization
A strength of the MC method is its ability to accurately
compute dose for complex dose delivery scenarios such as
encountered in IMRT. IMRT often involves large intensity
gradients and is usually delivered using a sequence of small
static or dynamically shaped MLC segments. Under these
circumstances, the assumptions used in conventional algo-
rithms regarding scatter equilibrium and output ratio varia-
tion with field size often break down.185 Additionally, in
IMRT a significant fraction of dose to structures of interest
particularly dose limiting critical structures is due to radia-
tion scattered from or transmitted through the MLC.186 MC
simulation circumvents these limitations since it makes no
assumptions regarding radiation equilibrium and can trans-
port particles through the detailed MLC leaf
geometry87,137,187 to include MLC leakage radiation, even for
138,188,189
FIG. 7. Mass collision stopping power divided by the mass collision stop-
ping power of water as a function of density normalized to water. A com-
parison of the fit function to the ICRU data Ref. 177 for body tissues for
electron energies of 5, 15, and 30 MeV is shown. The few points outside the
curve are materials like urinary stones, which are considered to have negli-
gible effects. Reprinted from Kawrakow et al. Ref. 37 with permission.dynamic MLC leaf sequences.
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method used to incorporate the MLC into the dose calcula-
tion. Intensity modulation has been incorporated into MC
simulation using the conventional planning system’s inten-
sity matrix,190 independently generated fluence modification
matrices,87,92,191,192 or direct transport through the MLC.61,189
Note that errors introduced by fluence approximations used
during the MC dose calculation will be propagated through
to the prediction of the patient’s dose. Thus, when a fluence
matrix approach is used for MC dose calculations, differ-
ences with respect to a conventional algorithm’s heterogene-
ity correction will be detected, but fluence prediction errors
may go undetected, particularly if the same fluence matrix is
used both for the conventional and MC calculations. How-
ever, when MC simulation is used to transport directly
through the detailed MLC geometry, these fluence errors
should be detected. Accounting for geometric details in the
MLC geometry, such as interleaf leakage is possible using a
fluence matrix approach, however, will require a very high
resolution calculation matrix, which may be a limiting factor.
Moreover, the energies of the scattered particles through the
MLC using such an approach will be approximate. Whether
or not modeling the intricate details of the MLC versus
more approximate fluence matrix approaches will lead to
clinically significant differences in IMRT treatment planning
is not a fully resolved issue. More treatment planning studies
in this area of research are necessary to better understand the
associated clinical implications.
Application of the MC method for IMRT QA has been
demonstrated by several research groups61,87,139,190,192–194 us-
ing MC simulation to recompute dose distributions opti-
mized with the conventional dose planning algorithm. When
using MC calculations as the reference plan and ignoring
statistical fluctuations, dose differences between conven-
tional and MC algorithms can be considered systematic.195
Ma et al.191 found dose errors in excess of 5% and 20%
relative to the prescribed dose in targets and critical struc-
tures respectively due to patient heterogeneities, in compar-
ing MC calculations employing an independent fluence ma-
trix with a pencil-beam model. In comparing MC
calculations with a conventional planning system’s pencil-
beam model intensity matrix for head and neck and lung
cases, Wang et al.190 found a 20% lower V95 volume receiv-
ing at least 95% of the target dose for a lung plan, and a 9%
lower D95 dose delivered to at least 95% of the target vol-
ume for a head and neck plan. Average agreement among all
head/neck and lung cases in this study, however, was quite
good.190 Regarding the transport of particles through the
MLC, Siebers and Mohan61 showed fluence-based IMRT
dose underestimates of 4.5% in V95 and heterogeneity-based
dose overestimates of 5% in V15 in the same treatment plan.
In intercomparing MC codes, Reynaert et al.196 reported de-
viations of up to 10% in DVHs between PEREGRINE and
BEAMnrc calculations. These discrepancies were attributed
to differences in modeling of the Elekta SLi-plus MLC, not
caused by the particle transport in the patient. This study
further illustrates the importance of careful modeling of the
details of the MLC in IMRT treatment planning.
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cal availability of MC calculation as a whole and the large
calculation time required to perform the multiple IMRT dose
calculations required for optimization. MC simulation during
optimization allows the optimizer to account for heterogene-
ity induced dose perturbations, as well as for MLC leakage
and scattered radiation. Inaccurate dose algorithms used dur-
ing optimization can result in convergence errors195 in which
the optimized fluence pattern differs from that corresponding
to the optimal dose distribution.
Studies demonstrating the use of the MC method in IMRT
optimization include the work of Laub et al.,197 who utilized
a MC algorithm to evaluate the cost function during optimi-
zation but a pencil beam to compute the cost function deriva-
tives used by the optimizer. Jeraj et al.,195 reported on con-
vergence and systematic errors in the IMRT inverse planning
process for lung cancer resulting from the use of
convolution/superposition and pencil beam algorithms, ver-
sus the Monte Carlo method. A similar study for treatment
planning of head and neck cancers was published by Dogan
et al.198 Another study by Siebers et al.199 demonstrated the
use of correction-based schemes to produce convergence of
doses computed by conventional algorithms with MC calcu-
lations. Bergman et al.200 reported on the use of an EGSnrc-
based MC beamlet dose distribution matrix for IMRT plan-
ning using a direct aperture optimization algorithm. The goal
of their work was to assess the improvement in accuracy
over conventional algorithms in using MC methods for both
the final dose calculation as well as in the inverse planning
process.200 Combining these methods with statistical smooth-
ing and denoising techniques,166–172 after comprehensive
benchmarking, may allow introduction of MC-based IMRT
optimization into routine clinical practice, particularly since
it has been shown that cost functions converge faster than
individual dose uncertainties.161 For a review of other stud-
ies, the reader is referred to the article by Verhaegen and
Seuntjens.25
III.D.6. Voxel size effects
As is the case with any dose calculation algorithm, calcu-
lated dose is affected by the size of the scoring voxel. For
MC calculations, typical values in the scoring dimension are
voxel sides of 2–5 mm for field sizes greater than 3
3 cm2 and 1–2 mm for field sizes less than 33 cm2. For
calculations where geometric details of the MLC are in-
cluded in the modeling, scoring voxel sizes no larger than
1–2 mm will be necessary to diminish volume averaging of
dose from inter- and intraleaf leakage. As with conventional
algorithms, MC-based IMRT calculations should be per-
formed using voxel sizes of 2–3 mm or less in the high
gradient regions.201,202 In addition to affecting the spatial
resolution, the statistical uncertainty will be influenced by
the voxel size; reducing the voxel size will increase the rela-
tive uncertainty for a fixed number of source particles be-
cause fewer particles deposit dose in the smaller volume.
Increasing the voxel size and, hence, volume will reduce
the relative uncertainty but may introduce errors due to re-
4839 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4839duced spatial resolution. An example of the influence of
volume-averaging effects resulting from the use of larger
voxel sizes 
0.5 cm on each side in MC electron calcula-
tions is discussed in Sec. III E 3.5.
III.D.7. Cross sections
The uncertainties in photon interaction cross section data
in the energy range from 5 keV to a few MeV is of the order
of 1%−2%.203 Although many MC codes use the incoherent-
scattering-factor approximation which assumes scattering of
photons from stationary, free electrons, this approximation
is found to be accurate in the mega-voltage energy regime,
where the energy of the incident photon is much higher than
that of the electron K-shell binding energy.204 An excellent
review of the cross sections for bremsstrahlung production
and electron-impact ionization has been provided by
Seltzer.205 It is shown that, in general, calculated cross sec-
tions for the various electron interaction processes are in
agreement with measurements within the combined experi-
mental and theoretical uncertainties.205 It is felt that cross
section and electron data in the megavoltage energy range
are sufficiently accurate,206 assuming that sampling of these
cross sections is done accurately within a given code. These
same effects will be present in doses computed with the
convolution/superposition algorithm.
III.E. Experimental verification
III.E.1. Introduction
In this report experimental verification of the MC algo-
rithm deals with how accurately the algorithm performs un-
der different test conditions within a phantom. As with any
algorithm, verification and testing is a necessary step to en-
sure safety of use in the clinical setting. It is the consensus of
this task group that verification of a MC algorithm should be
similar to that of any model-based dose calculation algo-
rithm, such as convolution/superposition. The clinical com-
missioning and acceptance testing of dose calculation algo-
rithms has been reported.48–50 Additional testing to confirm
the accuracy of the MC algorithm in situations of electronic
disequilibrium will be helpful. Quantification of benchmark
cases such as the ICCR benchmark99 should be performed
by either the user, or the vendor. The intent of this section is
to provide some examples of additional types of testing that
may be included to assure the accuracy of the MC algorithm.
The specification of required measurements for acceptance
testing and commissioning of the MC algorithm and the cri-
teria for algorithmic agreement with measurements is beyond
the scope of this report.
III.E.2. Previous work
Toward the goal of verification of dose calculation algo-
rithms, there have been a variety of studies related to mea-
surements in heterogeneous media. These investigations see,
for example, Refs. 207–212 have usually focused on estab-
lishing limitations of conventional dose algorithms in hetero-
geneous media and on how the use of physics-based algo-
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used to produce more accurate results. More recently, Arn-
field et al.213 found large differences up to 10% between
collapsed cone convolution and MC PEREGRINE calcula-
tions in an 8 cm lung-equivalent slab embedded within solid
water and irradiated by a 44 cm2, 18 MV photon beam.
Their work included film and ion chamber detectors and
showed that MC calculations were in good agreement with
measurements.213
With respect to patient planning, studies91,115,214–219 have
pointed out major differences between MC calculation and
conventional methods, such as the 3D pencil beam and
convolution/superposition algorithms. Over the past ten
years, there has been a growing interest in the use of the MC
method in clinical treatment applications with many institu-
tions around the world actively involved in the development
and testing of such systems. Many experiments in homoge-
neous and heterogeneous
phantoms26,27,71,75,82,84,86,93,96,115,119,194,213,220–225 have been
directed toward verification of MC algorithms for clinical
planning applications. The interested reader is referred to
these and other related publications for a comprehensive re-
view of the various types of experimental testing of MC
treatment planning algorithms.
III.E.3. Types of verification experiments
Experimental verification of a MC algorithm should in-
clude testing to assess the accuracy of: a the beam model
be it measurement-driven or based on treatment head simu-
lation and b the radiation transport algorithm in homoge-
neous and heterogeneous phantoms. The former is part of
routine commissioning of dose calculation algorithms,
whereas the latter is likely to have significantly more in-
volvement from developers and vendors.
III.E.3.a. The beam model. The purpose of verification
of the beam treatment head model is to ensure that param-
eters, such as the incident beam energy if used are correctly
“tuned” to produce dose distributions in agreement with
measurement. Such verification is the same as that for any
dose algorithm and may best be performed with measure-
ments in a homogeneous water phantom. These tests
should include the acquisition of depth and profile doses in a
water phantom for a range of field sizes, as is routinely per-
formed for conventional algorithmic verification, and docu-
mented in the AAPM TG-53 report.48–50 In addition, the use
of measured in-air off axis ratios may be useful for bench-
marking the beam model. Calculated in-air off-axis ratios
have been shown to be very sensitive to the incident electron
beam parameters e.g., mean energy, intensity distribution,
etc., as well as the dimensions and densities of other struc-
tures, such as the primary collimator and flattening filter.102
The multileaf collimator (MLC). Experiments to bench-
mark the MLC transport have ranged from arbitrarily shaped
AP fields designed to verify overall penumbral and transmis-
sion dose88 to more complicated MLC shapes designed to
test modeling of detailed effects, such as transport through
83,87,226the rounded leaf ends, tongue-and-groove
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The complexity of MLC verification experiments will de-
pend on the usage of the MC algorithm in the clinical setting.
For the purposes of 3D conformal radiotherapy 3D-CRT,
the shaped field cases provided in Fig. A3–1 of the AAPM
TG-53 Ref. 48 report are good examples of tests designed
to test overall MLC transmission and penumbral effects. In
the context of 3D-CRT planning, the accurate modeling of
details of the MLC and the influence of these effects on leaf
transmission and penumbra may be of reduced clinical im-
portance to the target doses for an appropriate CTV-to-PTV
margin as these issues affect the dose at the field edges and
outside the field.227 For IMRT, it is now well established that
the accurate modeling of MLC transmission and penumbra is
critical.61,227 A stringent test of the ability of the MLC model
to accurately handle intra/interleaf transmission is presented
in Fig. 8a, for a Varian, Millenium 120-leaf MLC. In this
example, the calculated MLC leakage radiation is compared
with film measurements in a direction perpendicular to the
leaf motion.83 Figure 8b shows a comparison between MC
calculations and film measurements for a MLC “picket
fence” shape where the field is blocked by even numbered
MLC leaves with odd numbered leaves retracted behind the
jaws.83 This test is useful in evaluating how accurately the
tongue-and-groove effect is handled.
In designing a test suite for verification of the MLC trans-
port accuracy, the clinical physicist should give special con-
sideration to the detailed specifications of the MLC, particu-
larly if the MC model is to be used for IMRT planning.
These details include: density and composition of the MLC
leaves, rounded leaf-end dimensions, intra/interleaf gaps, and
tongue-and-groove dimensions. Discrepancies between MC
calculations and measurements deemed significant by the
physicist should be reported to the vendor; modification of
the relevant parameters influencing the model accuracy, such
as the MLC geometric model should be performed by the
vendor to establish acceptable agreement between calcula-
tions and measurements.
Other beam modifying devices. The accuracy of MC
simulation of beam modifying devices, such as wedges and
blocks may be benchmarked using methods similar to that
for conventional algorithms.48 A publication on the experi-
mental verification of the PEREGRINE MC system27 included
the acquisition of large wedged field profiles 4020 cm2
at various depths see Fig. 13 of Hartmann-Siantar et al.27.
The purpose of large field testing is to ensure that radiation
transport through the wedge or other beam modifying de-
vice is in acceptable agreement with measurements across
the entire physical range of the device. Unacceptable differ-
ences between calculations and measurements should be re-
ported to the vendor—appropriate action should be taken by
the vendor to help resolve these differences.
III.E.4. Verification of the Monte Carlo transport
algorithm in phantom
Given the improvement in the accuracy of MC simulation
over conventional algorithms, particularly under circum-
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algorithm should include testing under these types of condi-
tions to confirm the expected accuracy. Although reports,
such as the AAPM TG-53 Ref. 48 and others,49,50 recom-
mend testing in heterogeneous phantoms, issues related to
electronic disequilibrium are generally excluded. This task
group strongly encourages that verification testing of the MC
algorithm include experiments emphasizing electronic dis-
FIG. 8. a Measured solid line and calculated dashed line MLC leakage
radiation perpendicular to the direction of MLC leaf motion for a 10
10 cm2 MLC-blocked field for 6 and 18 MV beams. Dose calculation and
measurement for the 6 MV beams occurred at 5 cm depth, 95 cm SSD, and
the 18 MV data at 10 cm depth, 90 cm SSD. One should note that the dose
due to leakage radiation under the closed leafs typically accounts for 2%
−3% of the open field dose. The discrepancy noted for the 18 MV compari-
son is roughly 0.1% of the open field dose and is most likely to a small
difference in the MLC density used in the calculations Ref. 83. Reprinted
from Siebers et al. Ref. 83 with permission. b Measured solid line and
calculated dashed line doses for 6 and 18 MV 1010 cm2 field a
blocked by even numbered MLC leaves with odd numbered MLC leaves
retracted behind the jaws. One should note that the dose due to leakage
radiation under the closed leafs typically accounts for 2%−3% of the open
field dose. Reprinted from Siebers et al. Ref. 83 with permission.equilibrium effects, in addition to standard tests in heteroge-
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type of testing is needed to exploit the advantages of MC-
based simulation to its full potential.
Verification measurements in slab phantoms with embed-
ded low density inserts and irradiated by high energy pho-
tons are useful in assessing the transport accuracy under con-
ditions of electronic disequilibrium.84,213,220 Effects of
penumbral broadening of the dose distribution resulting from
lateral electron transport may be evaluated using such
phantoms.84,213,220
Dose measurements at various locations depths and off-
axis distances both within and outside a high-density hetero-
geneity provide a benchmark to evaluate the perturbation of
the photon and electron fluence due to the presence of the
heterogeneity.225 Dosimetric effects at interfaces e.g., due to
backscattering at bone/tissue interfaces53,225, transport
within the heterogeneity, and the doses outside the heteroge-
neity may all be assessed with careful positioning of mea-
surement devices within the heterogeneous phantom.
Experimental verification should also be performed in
more clinically relevant situations. Examples of such geom-
etries include thorax phantoms,228 and mediastinal229 and
tumor-like phantoms.229,230
Verification experiments for algorithmic verification have
also included the use of anthropomorphic Rando phantoms,
where TLDs are most often used for the measurements.225,231
With anthropomorphic phantoms, calculated patient treat-
ment plans may be verified under a range of clinical circum-
stances. However, measurements must be carried out care-
fully with appropriate experimental techniques, theoretical
interpretation, and reproducibility.
III.E.5. Dose buildup region
It is challenging to make accurate measurements in the
dose buildup region. A recent study by Abdel-Rahman et
al.152 showed significant differences see Fig. 9 in the dose
FIG. 9. Measured percent depth ionization and Monte Carlo calculated per-
cent depth dose in the dose buildup region in water with the IC-10 cylindri-
cal ionization chamber and the Roos parallel-plate ionization chamber in
water for a 1010 cm2 field and SSD of 100 cm, for an 18 MV x-ray
beam. For the IC-10 ion chamber, the effective point of measurement was
1.8 mm upstream from the chamber center. Reprinted from Abdel-Rahman
et al. Ref. 152 with permission.buildup region 
1 cm between the response of a parallel
Medical Physics, Vol. 34, No. 12, December 2007plate Roos and cylindrical ion chambers IC-10, Scan-
ditronix in both 6 and 18 MV photon beams. Similar differ-
ences were found between a cylindrical ion chamber and a
parallel plate chamber P11 and a stereotactic diode Scan-
ditronix by Yokoyama et al.232 who measured dose buildup
regions for IMRT fields. Based on the available literature, it
is therefore recommended that dose buildups be carefully
measured with either a parallel plate chamber, an extrapola-
tion chamber, or with methods such as TLD extrapolation.233
Diode detectors may also be considered for dose buildup
measurements234 but should be cross referenced with other
detectors, such as parallel plate ion chambers. As pointed out
by Kawrakow155 see Sec. III C 4, the relationship between
the measured ionization and dose is sensitive to details of the
ion chamber design and needs to be accounted for in dose
buildup measurements.
III.E.6. Output ratios
MC calculations of output should be performed in a
measurement-like geometry, usually consisting of a central
axis point dose estimate at a fixed depth dmax, 10 cm or
other in a water phantom for square field sizes defined by
the collimating jaws. If the backscattered radiation into the
monitor chamber is correctly modeled, it is possible to cal-
culate output ratios to within 1%−2% agreement with mea-
surements over a range of square field sizes, with sides from
3 to 40 cm.146 In addition, comprehensive verification of out-
put ratios should include testing for small segmental fields
located off-axis, which are commonly used in IMRT plan-
ning. Output ratios should be verified against measurements
of specially designed IMRT fields, such as junction narrow
slit fields, in which the effects of small field dosimetry are
magnified. Examples of such fields have been
reported.83,87,145,187
III.E.7. Electron beams
Careful experimental verification is especially necessary
for electrons because the tolerance of parameters, such as the
electron energy and the treatment head structure constituents
are much tighter than for photons. Accurate measurements
are a prerequisite to accurate simulation. Care must be taken
in measurement of the central axis depth-dose curve used to
define the beam energy. Profiles in large fields need to be
included to determine geometry details such as the distance
between the scattering foils, the thickness of these foils, and
the lateral position of shaped scattering foils, if present. Mea-
surement of dose profiles in the bremsstrahlung tail are help-
ful to validate the photon component of the beam model.112
Comparison to measured output ratios and dose distributions
over the full clinical range of field sizes and SSDs is neces-
sary for each applicator and beam energy, to rigorously vali-
date the dose calculation. Further measurements, such as
dose measured in an anthropomorphic phantom,221 should be
performed to validate the beam model for the specific MC-
based application.
Comprehensive verification for electron beam MC simu-
lation should include measurements in heterogeneous phan-
4842 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4842toms, such as those reported in the Electron Collaborative
Working Group report235 and its update.236 Cygler et al.26
performed experimental benchmarks using a variety of het-
erogeneous phantoms, including a 1D slab geometry with an
aluminum slab insert, a 2D geometry with cortical bone-
equivalent inserts “ribs” geometry, a 3D cylindrical geom-
etry with an “air” insert, and a complex trachea and spine
equivalent geometry. Figure 10 shows the example trachea
and spine phantom used in their study.26 Differences between
measurements and calculations in this example were shown
to be due to the volume averaging effects of a large voxel
size 
0.5 cm.26 The MC calculations are found to under-
estimate the measurements because the large voxel size av-
erages the density distribution in the vicinity of the hetero-
geneity, effectively reducing the calculated dose across the
low-density heterogeneity.26
Careful measurements in such heterogeneous phantoms
will provide rigorous benchmark data for verification of the
MC algorithm, and as such should be strongly considered for
testing purposes.
III.E.8. Measurement uncertainties
Making dose measurements is fraught with problems if
FIG. 10. Trachea and spine phantom: measured and Monte Carlo Master-
plan, Nucletron, based on VMC++ calculated crossplane dose profiles at
various depths for: a 9 and b 20 MeV. SSD=100 cm, 1010 cm2 ap-
plicator. Monte Carlo simulations were performed with
50 000 histories /cm2 and a voxel size of 0.49 cm. 100 MU were used for
the calculations. The relative uncertainty in the calculations is about 1%
−1.5%. The phantom geometry is shown in the inset. Differences between
measurements and calculations in this example were attributed to the vol-
ume averaging effects of a large voxel size 
0.5 cm Ref. 26. Reprinted
from Cygler et al. Ref. 26 with permission.the aim is to verify calculations at the 2% or better level,
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take into account point of measurement effects, variations in
stopping power ratios for ion chambers, and beam quality
dependence in general for other detectors e.g., the well
known over-response of film in regions of low mean photon
energy, polarity effects, ion recombination effects, and
chamber perturbation effects. Specific detectors may be re-
quired for accurate measurements under specific conditions;
for example, properly constructed parallel plate chambers
may be favored over ion chambers for measurements in the
dose buildup region or at material interfaces. Uncertainties
due to improper detector positioning must also be quantified
as these measurements are often performed in regions of
high dose gradients.
When using modern IMRT techniques there can be strong
perturbation effects or corrections needed with ion chamber
and other detector measurements. However, as with other
algorithms, detector perturbations are generally not ac-
counted for in verification of MC-based treatment planning
algorithms. MC methods may be used to model the physical
details of the detectors to provide a better understanding of
measurements performed under nonequilibrium conditions.
These approaches are available to developers of MC tech-
niques but further advancement and investigation of this
technology is necessary before specific recommendations
can be made. Measurements form the basis for benchmark-
ing the accuracy of dose calculation algorithms in clinical
radiotherapy. It is therefore important that the uncertainties
in the measuring techniques be accounted for.
III.E.9. Example experimental tests
Example tests for verification of MC dose algorithms are
provided in Table IV. These tests, intended as a supplement
to those provided in the AAPM TG 53 report,48 aim to evalu-
ate the various components of the MC algorithm.
III.E.10. Timing issues
The issue of calculation time is of considerable impor-
tance in the clinical treatment planning process. To provide a
perspective on this subject, users of commercial MC dose
algorithms were asked to submit calculation times for photon
and electron treatment plans. The treatment plans ranged in
complexity from simple AP beams to dynamically delivered
IMRT plans. These results are summarized in Table V. As
noted in Table V, photon beam calculations with PEREGRINE
are approximately a factor of 2–3 times slower than those for
conventional planning systems. However, these times will be
reduced using faster, currently available processors 
2 GHz versus 800 MHz. Electron beam calculations with
VMC++ Nucletron are roughly equivalent in processing
times to conventional systems. The timing comparisons pro-
vide good justification of the fact that significant processing
times are no longer a concern for routine clinical MC dose
calculation. MC calculations for a plan with one beam take
the same time as that for a plan with multiple beams of
approximately the same field size, for the same statistical
uncertainty to the PTV. This is because the statistical uncer-
4843 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4843tainty is determined by the number of particles passing
through a volume, and this number can be held constant
when performing a MC plan with multiple beams. This is a
distinct advantage over conventional algorithms where com-
putational time scales linearly with the number of beams.
IV. CLINICAL IMPLICATIONS OF MONTE
CARLO-CALCULATED DOSE DISTRIBUTIONS
IV.A. Introduction
In spite of our confidence in the improved dose calcula-
TABLE IV. Partial listing of example specific tests, phantom designs, and det
intended as a supplement to those detailed in the AAPM TG-53 Ref. 48 a
that extreme care should be taken when performing many of these measure
conditions.
Test description Re
• Water depth doses and profiles—emphasis on
large open field sizes, 3030 cm2
• 2D planar dose perpendicular to the beam cax
for large open fields
To evaluate the b
model accuracy—
structures like the
and other parame
electron-on-target
• 2D planar dose perpendicular to the beam cax
of large MLC-shaped fields see Fig. A3–1 of
the AAPM TG 53 reporta
• Dose profiles under the closed MLC leaves,
perpendicular to the direction of motion see Fig. 7.b
To evaluate the ac
model, leaf-tip pe
and leaf transmiss
• Small field 11 cm2−44 cm2 depth doses
in low density media; larger field sizes should
also be tested.
• Penumbral broadening; lateral dose spreading
in lung assessed over a range of field sizes
22−3030 cm2.
To evaluate the tr
algorithm accurac
high energies 1
and low density m
electronic disequi
• Depth doses in high density media over a range
of field sizes, 33−3030 cm2.
To evaluate the tr
accuracy in high
as cortical-bone e
• Point doses in the vicinity of tissue interfaces tissue/
lung and tissue/bone, over a range of field sizes, 33
−3030 cm2.
To evaluate the al
accuracy in
the perturbed dos
interfaces.
• Dose evaluation in clinical treatment planning, for
simple, intermediate and complex static treatment plans
as well as IMRT plans, in anthropomorphic phantoms.
To assess the accu
calculation to poi
structures of diffe
densities and rece
doses based on th
aSee Ref. 48.
bSee Ref. 83.
cSee Ref. 229.
dSee Ref. 222.tion accuracy with a suitably commissioned clinical MC al-
Medical Physics, Vol. 34, No. 12, December 2007gorithm, we are confronted with the following clinical ques-
tion: What is the effect of more accurate MC dose
distributions on patient clinical outcome? To answer this
question, we will need to investigate the correlation of MC
calculated dose distributions with clinical outcome in terms
of tumor control and normal tissue toxicity.
To date the evidence directly correlating the improved
accuracy of MC-calculated dose distributions with clinical
outcome is scant. Investigations by De Jaeger et al.,237
which included convolution but not MC calculations,
238 239
measurements for Monte Carlo treatment planning systems. These tests are
er related publications Refs. 49 and 50 for algorithmic verification. Note
s as they are, in some instances, highly sensitive to the measurement setup
Phantom design
s sensitive to
ning filter
uch as the
y.
• Depth doses and profiles at
multiple depths measured in
a water phantom using a cylindrical
ion chamber.• 2D planar dose at multiple depths
in solid water using film.
y of the MLC
ra
• 2D planar dose at multiple depths
in solid water using film.
• Dose profiles under closed MLC leaves
measured with film or small volume
detector diode, TLD, pinpoint chamber,
diamond detector.
rt
se of
V
emphasizes
m effects.
• Depth doses in a layered phantom
see Fig. 8 and Fig. 1 of Rice et al.c
consisting of solid water and low density
material lung equivalent or cork
measured with small volume detector
diode, TLD, pinpoint chamber, diamond
detector, at multiple point depths or with film.
Beam is directed perpendicularly to the slabs.
• 2D penumbral measurements with film in planes
perpendicular to the beam cax at depths above, below,
and within the low density slab in the layered phantom.
Beam should also be directed parallel to the slabs to
evaluate interface effects.d
rt algorithm
ty media, such
lent slabs.
• Depth doses in a layered phantom consisting of solid
water and high density material cortical bone
equivalent measured with small volume detector diode,
TLD, pinpoint chamber, diamond detector for smaller
field sizes, or with film.
mic
at tissue
See, for example, Fig. 1 of Ref. 230. Dose measured
with film or with small volume detector, where possible,
at incremental depths, for example, 0.2, 0.5, 1.0, 2.0, and
5.0 cm anterior/posterior to the medial and proximal
tissue/lung equivalent and tissue/bone-equivalent
interfaces.
of dose
cated within
different
tment plan.
• Dose measured with small
volume detectors within
inserts of different materials,
ranging from air to cortical
bone-equivalent. Plans designed should
include simple, intermediate, complex static and IMRT
beam arrangements. Anthropomorphic phantoms should
be CT-imaged for planning purposes.ector
nd oth
ment
ason
eam
test i
flatte
ters, s
energ
curac
numb
ion.
anspo
y—u
0 M
edia
libriu
anspo
densi
quiva
gorith
e field
racy
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rent
iving
e treaChetty et al., and Lindsay et al. are among the first
4844 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4844studies evaluating the influence of improved dose distribu-
tions on outcome observed in patients treated with lung can-
cer. The study by De Jaeger et al.,237 in which lung cancer
treatment plans were retrospectively recalculated using a
convolution/superposition CS-based algorithm initially
calculated with an equivalent-path-length EPL algorithm,
showed clinically significant differences between calculated
and observed incidences of radiation pneumonitis. They
demonstrated that the calculated incidence of radiation pneu-
monitis correlated better with observed incidence when using
dose distributions calculated with CS rather than EPL
algorithms.237 Although this study was carried out using a CS
algorithm, it provides strong support that the dose-response
relationships determined with correction-based algorithms
will be different than those computed with model-based
methods.237 With the sometimes large differences observed
between the doses calculated with CS and MC algorithms,240
the MC method is likely to add a higher degree of accuracy
to the dose-effect relationships, and will be instrumental in
putting these relationships on a more solid footing.
There is clearly a need for more studies addressing the
clinical impact of MC-calculated dose distributions. The use
of retrospective data may provide a useful means to perform
such studies. Retrospective dose assessments of already ex-
isting local tumor control and normal tissue complications,
using doses recalculated with MC algorithms, may give an
early indication of the clinical utility of the MC method, and
may also help physicians determine how to use the new MC-
calculated doses.206 Retrospective analyses should eventually
show us how to make use of this information in a prospective
206
TABLE V. Summary of timing results for clinical treatment plans from curr
provided by author G.E., performed using the PEREGRINE Nomos division
conducted with Nucletron. The 1 relative statistical uncertainty was appro
1%−1.5% in the average depth dose along the central axis for the Nu
uncertainty of 1%−2% in the mean dose of all voxels receiving more than
cautioned that the timing results are subject to large uncertainties due to dif
Monte Carlo code/configuration Des
PEREGRINE Nomos, North American Scientific 16
processors 8-dual, Pentium III, 800 MHz
AP beam, 6 MV
phantom, cubic v
5 field, 6 MV CR
voxels with 
2.4
5 field, 6 MV pr
with DMLC exp
with 
2.4 mm s
Masterplan VMC++, Nucletron, single CPU Pentium IV
XEON, 2.2 GHz
AP beam, 6 MeV
water phantom, c
AP beam, 17 Me
water phantom, c
AP beam, 20 Me
water phantom, c
Breast boost trea

33 cm cutou
eMC MMC, Eclipse, Varian single CPU Pentium IV
XEON, 2.4 GHz
AP beam, 6, 12,
applicator, water
sidesway.
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In reviewing the literature on clinical treatment planning,
one should keep in mind that the dose differences found
between MC-based and conventional algorithms will be
highly dependent on the beam arrangements, field sizes,
beam energies, tumor size, and location. This is particularly
true in anatomical sites where the target is situated near tis-
sues with widely varying densities, such as the lung and
head/neck. For example, due to electron transport issues, dif-
ferences found in a lung CRT treatment plan using small
field sizes and 15 MV photons may be much larger than
those found with a standard AP/PA lung plan, using large
field sizes and 6 MV photon beams. The reader should there-
fore be advised that, although there is a general consensus on
the importance of the MC method in sites such as the lung,
the dosimetry in many of the reported studies is based on
specific conditions. The following literature review will fo-
cus on treatment planning in the lung and head and neck
since differences between MC-based and conventional algo-
rithms are likely to be smaller in other external beam treat-
ment sites. This does not include the potential for improve-
ment in dose estimates in any site from accurate simulation
of beam modifiers, in particular, the MLC for delivering
IMRT. More studies using MC-based dose calculation tech-
niques in clinical treatment planning are warranted to better
quantify the dosimetric and clinical benefits of these algo-
available commercial Monte Carlo systems. Data for photon beams were
rth American Scientific system and those for electrons by author J.E.C.,
tely 2% in the maximum dose voxel for the Nomos calculations and roughly
n electron beam calculations. Eclipse calculations were reported with an
of the maximum dose within the body of the contour. Readers should be
ces in compilers, memory size, cache size, etc.
ion of treatment plan Time estimate
min
ns, 1010 cm2 in a water
with 2 mm sides
48
ostate plan, 
711 cm2, cubic
sides
89
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71
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4845 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4845An excellent review of MC-based dose calculation meth-
ods in clinical planning for various treatment sites, including
the breast and prostate is provided in the article by Reynaert
et al.241
IV.B.1. Photon beam treatment planning
IV.B.1.a. Lung Perhaps the strongest motivation for the
need for MC dose calculation comes from treatment plan-
ning for lung cancer. This is because electron transport is-
sues, not accounted for accurately with conventional algo-
rithms, are exacerbated in the low density tissues. A
consequence of electronic disequilibrium in the lung is the
underdosage of the PTV, as shown in Fig. 11. The penumbral
widening in the dose distribution as a result of the increased
electron scattering in the lung is illustrated for a conformal
lung plan in Fig. 12. Depending on the location and size of
the tumor, and the beam energy, underdosage of the PTV in
lung planning may be significant. In addition to the target
coverage, dose to normal tissues, particularly the normal
lung, may be equally affected. Numerous lung planning stud-
ies have shown sometimes substantial differences 10%
−20% between conventional and MC
algorithms.117,190,192,214,216,242–246
FIG. 11. Opposed, oblique field treatment plan 15 MV photons showing
the 100% isodose coverage for MC modified DPM, University of Michigan/
UMPlan in the solid line, and an equivalent path length EPL, University of
Michigan/UMPlan algorithm in the dashed line. The PTV is demarcated in
white.
FIG. 12. Isodose distributions for a 3D conformal lung plan 15 MV pho-
tons calculated using an equivalent path length EPL, University of
Michigan/UMPlan algorithm on the left and a MC calculation modified
DPM, UMPlan on the right. A distinct penumbral broadening in the MC-
based dose distribution on the right is observed due to the increased elec-
tron scattering in the lung tissue. This effect is not as pronounced in the
EPL-calculated dose distribution.
Medical Physics, Vol. 34, No. 12, December 2007Due to the complicated dosimetric issues associated with
treatment planning in the lung, more studies and compari-
sons using the MC method are encouraged. The utilization of
advanced techniques, such as extracranial stereotactic radio-
therapy using 10–24 Gy fractions,247 for the treatment of
early stage lung cancer, may increase the importance of ac-
curate dosimetry and the clinical importance of MC calcu-
lated doses. One of the important next steps must be to
evaluate how the improved MC dose distributions will clini-
cally impact outcome for tumors and normal tissues.
IV.B.1.b. Head and neck There have been numerous
studies on MC head and neck CRT and IMRT
planning.190,192,193,214,248–250 These studies have shown in
general that dose differences between convolution and MC
algorithms are dosimetrically insignificant. However, it has
also been shown that dose differences for tumors located in
the presence of air cavities can be significant due to inaccu-
rate calculation of the photon/electron energy fluence inside
and around air cavities using Batho and ETAR methods214 as
well as a collapsed cone convolution algorithm.250,251
IV.B.1.c. Other treatment sites Readers are encouraged
to review articles published on MC-based treatment planning
in other anatomical sites, which include: brain,89,91,219,252–254
breast,216,255 and prostate.193,214,216,256,257
IV.B.2. Electron beam treatment planning
There have been numerous studies on the use of MC cal-
culations in electron beam treatment plan-
ning.26,111,115,121,258–262 In some instances, significant differ-
ences between pencil beam dose distributions and MC cal-
culations have been demonstrated, particularly in regions in
or near air cavities and lung or bone tissues.115,263 Large
differences have also been observed for small irregular
fields, beams with oblique incidence, and for extended SSD
treatments.115,263 The use of the MC method represents a
significant improvement in accuracy for electron beam dose
calculation compared with conventional algorithms. Electron
MC calculations require far fewer primary histories to
achieve a given uncertainty on the dose being calculated be-
cause electrons deposit their energy in a more continuous
manner, in a smaller volume and mostly starting from the
same location the patient surface. This timing advantage
has allowed the development of commercial electron beam
MC algorithms which are time efficient taking on the order
of minutes per plan even on a single processor.26
From phantom and routine patient planning calculations
based on experience with a commercial electron beam MC
algorithm VMC++, currently Nucletron, Cygler et al.26 have
reported that MC-generated monitor unit MU values may
differ from the homogeneous water phantom values by as
much as 10%, depending on surface irregularities and inho-
mogeneities present in the irradiated volume. This situation
is frequently encountered for head and neck sites, especially
in the region of the nasal cavities. In such cases, surface
irregularities and missing tissue lateral to the air cavity ne-
cessitate larger MUs to deliver the same prescribed dose ver-
sus flat surface anatomies. As is the case with photon beams,
4846 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4846it is important that the statistical uncertainties in the single
voxel MU calculations be reported.
IV.C. Association of Monte Carlo calculated dose
distributions with clinical outcome
As with other changes to the therapy treatment process,
with the implementation of a new dose calculation algorithm
such as the MC method, users should correlate doses and
prescriptions with respect to previous clinical experience.
Chetty et al.238 studied dose-effect relationships for tu-
mor and normal tissues by recalculating dose distributions
retrospectively using the MC method for patients treated on a
nonsmall cell lung cancer NSCLC dose escalation
protocol264—original plans were generated using an EPL al-
gorithm. Follow-up data was evaluated from CT scans taken
six months to two years postradiation therapy. Follow-up CT
scans were fused with initial treatment planning scans and
the original and replanned dose distributions were mapped
onto the anatomy to establish associations between dose and
regions of local recurrence and normal lung damage
radiation-induced pneumonitis.238 Preliminary results of
this study showed that the originally planned PTVs are
sometimes significantly underdosed with MC calculations
compared with the EPL algorithm.238 For normal lung tissue,
the correlation of dose with normal tissue complications was
also found to differ, but also showed that beam model differ-
ences not related to the dose calculation algorithm in the
patient are important and must be considered for an unbi-
ased comparison of dose calculated by different
algorithms.136,238,241,265
Lindsay et al.239 performed retrospective MC-based recal-
culations of a large group of lung cancer treatment plans and
showed significant differences in dose indices V20, maxi-
mum lung dose and mean GTV dose between plans without
heterogeneity correction and MC calculations. Moreover,
correlations between V20 and observed radiation pneumoni-
tis in this study were found to be different between plans
without heterogeneity correction and MC-based treatment
plans.239
Despite the preliminary and somewhat anecdotal nature
of the evidence thus far, observations suggest that more ac-
curate dose calculations will reveal inadequate target cover-
age or hot spots in certain areas of organs at risk that could
lead to differences in outcome. Complete MC recalculations
of delivered dose distributions that include the effects of
other factors, such as organ motion and patient setup errors,
will be required to refine these correlation studies. In addi-
tion, it should be noted that the efficacy of radiation therapy
is also dependent upon individual patient response.
The clinical evidence thus far, albeit preliminary and ret-
rospective, provides support that dose delivery based on MC
treatment plans, particularly for lung cancer, have the poten-
tial to result in clinically significant changes. Kong et al.266
have shown that dose significantly impacts local control and
overall survival for NSCLC; local control was found to in-
crease at a rate of 1.3% per gray above the conventional dose
fractionation scheme 63–69 Gy in 2.0 Gy fractions. This
Medical Physics, Vol. 34, No. 12, December 2007suggests that even small differences in dose distributions, as
a result of inaccurate dose calculation, are likely to affect
local control and survival for patients with NSCLC. Further
studies of MC dose distributions in the lung and in other
sites, such as the head/neck, are necessary and are encour-
aged in order to unequivocally evaluate the clinical utility of
MC-calculated doses.
V. SUMMARY
We wish to reiterate that, from a clinical implementation
standpoint, the MC method should be treated as would any
conventional dose algorithm. Proper implementation will re-
quire the clinical physicist to understand, on some level, the
fundamentals of the algorithm as well as the possible pitfalls
associated with its clinical implementation, much as one
would for any dose algorithm. In addition to providing an
educational review of the MC dose calculation method, we
have identified issues that will need to be considered by de-
velopers, vendors, and end users of MC-based techniques,
ultimately to ensure that patient dose calculations are ef-
fected safely.
In conclusion, we present a summary of some of the is-
sues which are important in the implementation and clinical
use of MC dose calculation algorithms. The recommenda-
tions summarized here are not meant to be prescriptive;
rather they are intended as a preliminary guide for medical
physicists to ensure thoughtful and safe implementation of
clinical MC algorithms. We anticipate that many of the areas
of concern will be studied in further detail in future, more
specific task group reports.
V.A. Treatment head simulation
a Vendors of MC-based dose calculation systems should
be responsible for providing the necessary guidance
and assistance with the beam modeling and bench-
marking process. Such guidance includes the tuning of
parameters such as the electron energy, or the adjust-
ment of model parameters in measurement-driven
models to ensure that the beam model meets the re-
quired specifications.
b In reporting statistical uncertainties in the calculated
patient dose, vendors should properly account for latent
variance in the beam model if the model is based on
treatment head simulation. Further, if the latent vari-
ance is a significant contributor to the total variance the
number of phase-space particles in the beam simulation
should be increased.
V.B. Patient simulation
V.B.1. Statistical uncertainties
We recommend that quantities, such as FD0.5Dmax, or
FPTV, or FPRV for doses to the specific volumes, PTV or PRV
respectively, be adopted as a standard method of reporting
fractional statistical uncertainties in dose averaged over the
relevant volume. The sole use of dose uncertainties to indi-
4847 Chetty et al.: AAPM Task Group Report No. 105: Monte Carlo-based treatment planning 4847vidual voxels, such as the maximum dose voxel, Dmax,
should be avoided. Additionally, reporting of single voxel
doses or doses over patient subvolumes should be accompa-
nied by their respective statistical uncertainties. In situations
where doses in individual voxels are important, such as Dmax
to a serial organ like the spinal cord, it may be necessary to
simulate a large enough number of histories so that sDmax is
very small. This will ensure that the absolute uncertainty in
Dmax will also be small. The required statistical precision
required for individual voxel dose estimates should be de-
cided upon with guidance from the clinical team.
V.B.2. Variance reduction techniques, efficiency
enhancing methods, and other parameters
Users should understand the influence on the dose accu-
racy of variance reduction implementations and approximate
methods used to improve the calculation efficiency, as well
as any other accessible parameters of importance to the MC
dose algorithm. Appropriate documentation on the methods
used and their influence should be made available to the user.
More studies on the influence of efficiency enhancing meth-
ods in clinical treatment planning are warranted, as it is
likely that the tradeoffs between speed and accuracy will not
be the same in different anatomical sites.267 Where possible,
vendors should provide users with the flexibility to adjust
parameter inputs for these efficiency enhancement tech-
niques but implement default values which are conservative,
i.e., accurate in all situations.
V.B.3. Dose prescriptions
Vendors are strongly discouraged from using single voxel
point doses for dose prescription and monitor unit calcula-
tions in their MC-based treatment planning systems. Rather,
doses should be prescribed to volumes larger than a single
voxel, such as the volume contained by an isodose surface.
Current users of MC-based planning systems are encouraged
to find ways of circumventing point-based dose prescriptions
if their systems are not flexible enough to allow otherwise.
V.B.4. CT-to-material conversions
The use of conversion techniques based purely on mass
density i.e., assuming the only patient material is water, but
with varying density, as employed in conventional algo-
rithms, is discouraged with MC simulation because these
methods ignore dependencies of particle interactions on the
materials, which can lead to notable discrepancies in high
atomic number materials. The conversions should include the
use of both mass density and the atomic compositions of the
materials. Appropriate documentation on the CT number-to-
material conversion method used by the software should be
accessible to the user.
V.B.5. Dose-to-water and dose-to-medium
MC dose results should: a explicitly indicate the mate-
rial to which the dose is computed, b allow conversion
between Dm and Dw using the methods discussed in Sec.
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tions. It is strongly encouraged that appropriate documenta-
tion on the dose-to-water conversion method used by the
software be provided to the user.
V.C. Experimental verification
V.C.1. Examples of specific tests
In addition to the standard testing necessary for conven-
tional dose algorithms, it is strongly recommended that ad-
ditional tests e.g., as suggested in Sec. III E 3 be included
to evaluate the accuracy of MC calculations under situations
where the MC method is known to perform better than con-
ventional algorithms.
V.C.2. Verification calculations
MC verification calculations should be performed under
the same conditions as the experiments. Phantoms used
should be CT-imaged for planning purposes. Statistical un-
certainties for verification plans should be reported and in-
cluded in the comparison of calculations with measurements.
More studies of the influence of detector perturbations using
MC calculations are encouraged.
V.C.3. Measurement uncertainties
It is important for the user to understand the limitations of
the various measurement devices as they are used in different
situations. It is recommended that realistic measurement un-
certainties be assessed and included when evaluating MC
verification calculations against measurements.
Although the implementation of MC treatment planning
will require clinical physicists to once again understand a
new technology, one should view this in a positive light.
Properly implemented MC algorithms will provide dose cal-
culation with sufficient accuracy in at least a single instance
of the patient geometry such that dose calculation is no
longer a source of meaningful uncertainty in the radiotherapy
planning process. In addition, although the details are some-
times complex, the underlying idea of simulating the actual
transport of individual particles is simpler to understand than
many other algorithms because it is based on actual physical
processes familiar to the medical physicist. Finally, this may
well be the last new dose calculation algorithm that medical
physicists will need to learn since MC techniques provide the
highest level of accuracy for dose calculations in radio-
therapy treatment planning.
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